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ABSTRACT 
The current study compared personality characteristics and cognitive functioning 
(specifically, attentional bias) in a sample of adults who had experienced childhood trauma (the 
Trauma group) and a matched healthy control group. The study also examined the possible 
effects of the mu-opioid agonist buprenorphine on attentional bias in the Trauma group. As a 
preliminary step, the first objective explored in the current research was to examine the test-
retest reliability of the childhood trauma questionnaire-short form (CTQ-SF; Bernstein et al., 
2003), an instrument for which no test-retest reliability data is currently available. The CTQ-SF 
was administered to the sample on three separate occasions. 
Following this preliminary step, the next set of objectives explored in the current research 
involved three specific hypotheses: Hypothesis 1 stated that, with regard to behavioral inhibition 
system (BIS) and behavioral approach system (BAS) sensitivity, I predicted that adults with a 
history of childhood trauma would have heightened activation of the BIS. This increased BIS 
activity would, I predicted, be reflected in relatively higher scores on the BIS dimension of 
Carver and White’s (1994) BIS/BAS scale. No significant differences were predicted for BAS 
sensitivity. Hypothesis 2 stated that, with regard to performance on the Object Relocation Task, 
adults with a history of childhood trauma would demonstrate an information-processing bias for 
threat-related stimuli and avoidance of approach-related stimuli, reflected in significantly less 
error for relocating fearful faces to their original locations and more error for relocating angry 
and happy faces to their original locations, compared to healthy matched controls. Hypothesis 3 
stated that buprenorphine would alleviate the attentional bias for fearful faces described above. 
The data presented in this thesis showed that, as a measure of childhood trauma, the 
CTQ-SF generated good test-retest reliability on four of its five subscales over variable lengths 
of time, even given different methods of survey delivery across administrations. In addition, I 
found that participants with a history of childhood trauma did not differ from matched controls 
with regard to the current study’s indices of behavioral approach and inhibition, and with regard 
to attentional bias. Furthermore, buprenorphine demonstrated no observable alleviation of 
attentional bias in individuals with histories of early adversity. One possible explanation for the 
lack of between-group differences may be related to the moderate severity of adverse 
experiences reported by the Trauma group. 
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INTRODUCTION 
The lifetime prevalence of exposure to a traumatic stressor (with “stressor” taken as 
defined by the fourth edition of the Diagnostic and Statistical Manual of Mental Disorders 
(DSM-IV; American Psychiatric Association [APA], 1994)) is approximately 90% (Breslau et 
al., 1998). This epidemiologic statistic suggests that a great majority of people will be subjected 
to an experience that will elicit “intense fear, helplessness, or horror” (Criterion A2 of the DSM-
IV description) at one time or another throughout the course of our lives. For a subset of 
individuals, such a traumatic event will occur during childhood. A recent estimate for the 
prevalence of exposure to a traumatic stressor in childhood (i.e., up to 16 years of age) is 
approximately 67% (Copeland, Keeler, Angold, & Costello, 2007). This figure is particularly 
alarming given the vulnerability of the developing brain to severe stressors. 
During sensitive developmental periods in early life, the human brain may be particularly 
vulnerable to the effects of traumatic stressors. The neurophysiological effects of early childhood 
adversity are thought to predispose the young brain to develop along a pathway that is 
particularly sensitive to stress. For example, prolonged maternal separation in early life may 
produce a flooding of neurotransmitters and hormones which could affect myelination, neural 
morphology, neurogenesis, synaptogenesis, and additionally cause alterations in molecular 
organization in the young brain, which may lead to enhanced fearfulness and anxiety (Teicher, 
Andersen, Polcari, Anderson, & Navalta, 2002).  Such alterations have the effect of predisposing 
the individual to a range of psychiatric and cognitive disorders (Teicher et al., 2003). 
A meta-analysis (N = 77 separate empirical studies) found that the experience of early life 
trauma was a significant risk factor for the onset of posttraumatic stress disorder (PTSD) in later 
life (Brewin, Andrews, & Valentine, 2000). In a study examining four successive birth cohorts 
dating back to 1900, Dube, Felitti, Dong, Giles, and Anda (2003a) found a significant association 
between adverse childhood experiences and increased risk for depressed affect, suicide attempts, 
multiple sexual partners, sexually transmitted diseases, smoking, and alcoholism. Childhood 
trauma has also been linked to increased risk for, in adults, depressive disorders (Chapman et al., 
2004), bulimia nervosa (Wonderlich et al., 2007), illicit drug use (Dube et al., 2003b), obsessive-
compulsive disorder (Mathews, Kaur, & Stein, 2008), and a range of personality disorders 
(Johnson, Cohen, Brown, Smailes, & Bernstein, 1999; Sansone & Sansone, 2007). 
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The current study compares the personality characteristics and cognitive functioning 
(specifically, attentional bias) in a sample of adults who have experienced childhood trauma and 
a matched healthy control group. The study also examines the possible effects of the mu-opioid 
agonist buprenorphine on attentional bias in the Trauma group. Mu-opioids are associated with 
the attenuation of emotional and affective physiological responses to stressors (Drolet et al., 
2001) and may therefore have a dissipating effect on the fear response in individuals with 
elevated levels of anxiety (Panksepp, 2003), a trait that is commonly associated with individuals 
who have experienced early adversity. 
 
Personality Characteristics of Adult Survivors of Childhood Trauma 
In a prospective longitudinal study investigating the effects of early adversity on 
development of personality disorders in early adulthood, the experience of childhood abuse and 
neglect was found to quadruple the likelihood of having a personality disorder in early adulthood 
(Johnson et al., 1999). This finding remained significant after the effects of age, parental 
education, and parental psychiatric disorders were statistically controlled for in a sample of 
individuals with (n = 31) and without (n = 608) a history of childhood abuse and neglect. In 
addition, when looking at abuse and neglect separately, the authors found physical abuse to be 
associated with increased antisocial and depressive personality disorder symptoms; sexual abuse 
to be related to increased borderline personality disorder symptoms; and neglect to be associated 
with increased symptoms of avoidant, antisocial, borderline, narcissistic, and passive-aggressive 
personality disorders. Finally, being diagnosed with any one of 10 of the 12 personality disorders 
listed in the DSM-IV was associated with the experience of any form of childhood abuse or 
neglect.  
This seminal study highlighted a significant association between the experience of 
childhood adversity and the diagnosis of a personality disorder in adulthood. Its findings have 
largely been supported by subsequent research. For instance, Rojas and Pappagallo (2004) found 
that childhood histories of sexual and physical abuse were risk factors for the development of 
borderline personality disorder, antisocial personality disorder, and major depression during 
adulthood. Similarly, Sansone and Sansone (2006) identified significant associations between 
early adversity (e.g., physical abuse, emotional abuse, sexual abuse, physical neglect, etc.) and 
borderline, antisocial, paranoid, avoidant, and schizotypal personality disorders. 
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The experience of childhood trauma does not, of course, invariably result in the 
development of a DSM personality disorder during adulthood. However, by showing the 
increased presence of maladaptive personality traits in childhood trauma victims compared to 
healthy participants, the above studies emphasise the elevated risk that victims of childhood 
trauma have for developing disordered personalities during adulthood. Before moving further 
into the literature review, and in order to move the discussion away from DSM-defined 
personality disorder, it is useful to describe what psychological researchers mean when they refer 
to “personality traits”. A general definition of this concept holds that they represent stable, 
characteristic ways of thinking, feeling, and regulating affect within the individual (Daud, af 
Klinteberg, & Rydelius, 2008). Hence, personality traits ultimately determine the way an 
individual experiences the world. 
A trait that has consistently been associated with victims of early life stress is neuroticism 
(Allen & Lauterbach, 2007; Bunce, Larsen, & Petersen, 1995; Glaser, van Os, Partegijs, & 
Myin-Germeys, 2006; Lysaker, Meyer, Evans, Clements, & Marks, 2001; McFarlane et al., 
2005; Rosenman & Rodgers, 2006; Roy, 2002). Neuroticism is characterised by the chronic 
experience of negative affective states, such as depressed mood and anxiety, and a vulnerability 
to environmental stressors. Individuals high in neuroticism react more negatively to stress, and 
are thus more likely to interpret ordinary everyday scenarios as dangerous or threatening (Roy, 
2002). 
In line with these observations, Glaser et al. (2006) found that neuroticism was 
significantly related to the experience of daily life stress in adult victims of childhood trauma. 
Individuals high in neuroticism have also been found to be at increased risk for internalizing 
mental disorders (Clark, Watson, & Mineka, 1994). This latter term refers to conditions of 
internalized anxiety, such as phobias, panic disorder, depression, and other anxiety disorders. 
Externalizing disorders, in contrast, are behavioural disorders characterised by impulsivity or 
disinhibition, such as, attention-deficit/hyperactivity disorder (ADHD) and conduct disorder 
(Brenner, Beauchaine, & Sylvers, 2005; Daud et al., 2008). 
Other adult personality traits associated with the experience of childhood trauma are 
decreased conscientiousness and increased openness (Allen & Lauterbach, 2008; McFarlane et 
al., 2005). Interestingly, the findings of increased openness (i.e., openness to new experiences; 
curiosity; creativity; open-mindedness) in this population are initially counterintuitive when one 
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considers the neurotic traits of childhood trauma victims. However, Allen and Lauterbach (2008) 
argue that openness may lead to risky behaviours that make the trauma victim vulnerable to 
repeated exposure to trauma. A more optimistic view is shared by McFarlane et al. (2005), who 
state that the trait of openness might be an adaptation to the environmental stressors experienced 
in the trauma population. 
Research into adult personality traits associated with childhood trauma is currently 
scarce, but has gained momentum in recent years. In a long-term longitudinal study using 
randomly selected samples of adults in Australia (N = 7485), researchers investigated the effects 
of childhood adversity on multiple adult personality characteristics. The authors examined 
neuroticism, extraversion-introversion, psychoticism, behavioural inhibition and activation, and 
positive or negative affectivity (Rosenman & Rodgers, 2006).Findings showed adverse 
childhood experiences to significantly increase the risk of high neuroticism (odds ratio (OR) = 
2.6), negative affect (OR = 2.6), behavioural inhibition (OR = 1.7), and dissocial behaviour (OR 
= 1.7) in adult life. No significant effects were found for extraversion, psychoticism, or 
behavioural activation.  
BIS/BAS. The model of personality investigated in this research is the behavioural 
inhibition and activation system developed by Gray (1981, 1982). According to this model, the 
behavioural inhibition system (BIS) and the behavioural activation system (BAS) represent two 
distinct neural systems that mediate the motivational impulses of aversion and appetite, 
respectively. The bi-directional nature of the systems proposed in Gray’s model represents two 
dimensions of personality, namely, anxiety proneness (mediated by the BIS) and impulsivity 
(mediated by the BAS) (Carver & White, 1994). 
With regard to the neural bases of the BIS, it is proposed to encompass the amygdala and 
septo-hippocampal system, its monoaminergic afferents from the brain stem, and its neocortical 
projection to the frontal lobe (Gray, 1977, 1981, 1990). BIS activation controls the experience of 
anxiety in response to threatening stimuli, and may also underlie feelings of fear, anxiety, and 
sadness in response to threatening cues. Individuals with greater BIS sensitivity are thought to be 
more prone to anxiety when confronted with threatening cues (e.g., punishment, nonreward, and 
novelty) (Brenner et al., 2005; Carver & White, 1994). 
With regard to the neural bases of the BAS, it is mainly represented by catecholaminergic 
(and especially dopaminergic) pathways running through the ventral tegmental area and the 
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nucleus accumbens of the ventral striatum (Gray, 1981, 1987, 1990). Activation of this system 
controls goal-directed behaviour, and may also be responsible for the experience of positive 
emotions such as hope, elation, and happiness. Individuals with greater BAS sensitivity are said 
to be more prone to engage in goal directed behaviour and to experience positive feelings when 
exposed to cues of impending reward (Carver & White, 1994; Brenner et al., 2005). 
In addition, Gray’s model proposes that the two systems are neurobiologically arranged 
in a distinct manner so that no interaction exists between them. Sensitivity in BIS is therefore not 
related to sensitivity in BAS, and vice-versa. Studies investigating BIS/BAS activation typically 
use Carver and White’s (1994) BIS/BAS scales to measure sensitivity along the separate 
dimensions. Consistent with the independent nature of the systems, researchers often find 
significant effects on one of the dimensions (e.g., BIS; Rosenman & Rodgers, 2006) and not the 
other, or make predictions on only one of the dimensions (e.g., BAS; Harmon-Jones & Allen, 
1997). Researchers have examined numerous disorders associated with variations in the 
sensitivities of both the BIS and BAS, individually and in combination. 
Research suggests that heightened BIS activity, as measured by the BIS/BAS scales 
(Carver & White, 1994), is significantly associated with clinical levels of anxiety (Vervoort et 
al., 2010). Similarly, decreased BIS activation is associated with the type of disinhibition 
observed in ADHD (Quay, 1997). Under-activation in both the BIS and BAS, resulting in 
sensation-seeking behaviours, may be associated with behavioural symptoms typical of conduct 
disorder (Beauchaine, Katkin, Strassberg, & Snarr, 2001). Low BAS activity, resulting in a lack 
of positive experiences and expectancies, is related to the anhedonic symptoms of depression 
(Beevers & Meyer, 2002). Finally, heightened BAS activity, which is associated with increased 
reward responsiveness and risk-taking behaviours, has been linked to substance abuse and 
addiction (Franken, Muris, & Georgieva, 2006; Loxton & Dawe, 2001). 
There is a paucity of research investigating the behaviour inhibition and activation 
personality traits in adults with a history of childhood trauma. An understanding of these traits 
could have important clinical and pharmacological implications for the treatment and prevention 
of disorders associated with childhood trauma (Ballenger et al., 2004). However, findings 
suggest that higher levels of adverse childhood experiences significantly increase the risk of 
higher BIS sensitivity, with no significant relationship between childhood adversity and BAS 
(Rosenman & Rodgers, 2006). Such findings are to be expected given the relationship between 
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childhood trauma and anxiety-related personality traits such as neuroticism (see, e.g., Allen & 
Lauterbach, 2007; McFarlane et al., 2005; Rosenman & Rodgers, 2006), and given the fact that 
heightened BIS activation is associated with an increase in symptoms of anxiety (Vervoort et al., 
2010).  
The development of maladaptive personality traits in victims of childhood trauma. 
An important issue in research into the personality characteristics associated with childhood 
trauma is whether those characteristics are a consequence of the effects of early stressors on 
neurodevelopment, or whether they represent a pre-existing vulnerability to stress that intensifies 
the experience of traumatic events and thereby predisposes individuals to subsequent psychiatric 
and psychological disorders (Daud et al., 2008). Researchers are largely in agreement that 
despite potential pre-existing vulnerabilities to stress, repeated traumatic stress in childhood 
results in a cascade of neurodevelopment changes that directly influence subsequent adult 
personality characteristics (Ballenger et al., 2004; Perry, Pollard, Blakley, Baker, & Vigilante, 
1995; Teicher et al., 2002; Teicher et al., 2003). What is still at question, however, is the degree 
to which innate characteristics interact with experience to result in stable personality 
dispositions. For some investigators, the interaction does not lend itself to resolution, and they 
therefore take the position that research should focus on clarification, rather than resolution 
(Rosenman & Rodgers, 2006). 
Perry et al. (1995) suggest that traumatic experiences in childhood result in 
neurophysiological changes in the developing brain that, through repeated exposure, manifests in 
stable traits. The neural systems within the young brain do not all develop at an equal pace. 
Different systems undergo organization and differentiation at different times, during which they 
either require (critical periods) or are more sensitive to (sensitive periods) external environmental 
and internal neurochemical cues. Disruption of these critical cues may result from sensory 
deprivation during these periods, or from exposure to extreme stressors (e.g., traumatic 
experiences) and resultant abnormal neuronal activation. Once severe disruptions occur within 
critical or sensitive periods, the developing brain becomes particularly vulnerable to develop 
later psychopathology. For Perry et al., (1995), the mechanisms leading up to this state of 
vulnerability are defined by internalization of sensitized neurobiological states. 
Neurobiological systems are “use-dependent”, meaning, the more a system is activated, 
the more that state of activation (e.g., calm, fear, sleep) becomes entrenched in memory. The 
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neural system becomes sensitized to the stimuli that recurrently trigger it. Once sensitized, 
decreasingly intense stimuli become able to activate the same neural system. The system thereby 
becomes hypersensitive to those stimuli and the state of arousal thus becomes entrenched, that is, 
it becomes a trait marker of the individual. For Perry et al. (1994), those personality traits in 
victims of childhood trauma fall on two dimensions, namely, hyperarousal (what they call an 
internalized fight or flight stress response) and dissociation (what they call an internalized freeze 
and surrender stress response). These traits reflect initial response patterns to stressors that 
become pathological after repetitive stimulation through sensitization. Sensitization is primarily 
an adaptive response to external stimuli. However, in the case of trauma, repetitive or prolonged 
exposure may become maladaptive. Experiences during the critical developmental periods of 
early life may therefore inform the organization of brain systems. The use-dependent changes in 
neurodevelopment and organization predispose the victim of childhood trauma to a range of 
emotional, behavioral, cognitive, social, and physiological alterations (Perry et al., 1995). 
Teicher and colleagues (2002, 2003) express a very similar conceptualization of the 
course of neurodevelopment after traumatic experiences in the young brain. They state that a 
cascade of neurophysiological effects brought on by severe stress during sensitive or critical 
developmental periods in childhood predispose the young brain to develop along a stress-
responsive pathway that makes the individual vulnerable to high stress reactivity. This 
neurodevelopmental change may increase the possibility of cognitive disruption, such as a bias in 
information-processing.    
 
Information-Processing Bias in Adult Survivors of Childhood Trauma 
Information-processing bias refers to a bias in the way individuals process stimuli from 
the environment around them. Within the research setting, researchers may use emotionally-
laden words, or faces displaying various emotional reactions, as stimuli to investigate such bias. 
In such research contexts, an information-processing bias occurs when people attend to one type 
of emotion more than to another. Thus, some people may show a bias towards happy faces, and 
therefore spend more time attending to and focusing on those faces. Information processing 
requires attention, inhibition, and working memory and is therefore dependent on the executive 
control system, located in the pre-frontal cortex (PFC; Arnsten & Li, 2005). Furthermore, the 
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amygdala is uniquely implicated in the processing of emotional stimuli and the formation and 
recollection of emotional memory (McGaugh, 2000; Rolls, 2000; Teicher et al., 2002).  
Researchers have been able to identify various patterns of information-processing biases 
associated with specific psychiatric diagnoses. For instance, individuals with a diagnosis of 
PTSD have a specific bias towards threatening stimuli when compared to matched healthy 
controls (Dalgleish, Moradi, Taghavi, Neshat-Doost, & Yule, 2001; Moradi, Taghavi, Neshat-
Doost, Yule, & Dalgleish, 1999). These biases are fairly robust across cognitive processes (e.g., 
memory, attention, etc.) and stimuli form (e.g. words, faces, pictures, etc.; Bar-Haim, Lamy, 
Pergamin, Bakermans-Kranenberg, & Ijzendoorn, 2007). 
Research into attentional bias related to emotional stimuli stems from earlier 
investigations of temperaments and individual affective traits, in particular positive and negative 
affective traits. This research highlights asymmetrical brain activation associated with the quality 
of individual affective traits. Findings show, by and large, that processing of positive affective 
traits is associated with activation in the left frontal brain region, whereas that of negative 
affective traits is associated with activation in the right frontal region (Davidson, Jackson, & 
Kalin, 2000). Additional findings link positive emotional processing to left frontal activity, and 
negative emotional processing to right frontal activity. Together, these findings led to the 
conceptualization that the left frontal region only processes positive emotions, whereas the right 
frontal region only processes negative emotions (Heller, Nitschke, & Miller, 1998). Furthermore, 
researchers considered behavioural motivational direction (approach and avoidance/withdrawal) 
to be synonymous with emotional valence (i.e., approach tendency regarded as positive; 
withdrawal tendency is regarded as negative). This theoretical framework has come to be known 
as the affective valence hypothesis (Harmon-Jones, 2004). 
The affective valence hypothesis may lead to ambiguity in the outcomes and 
interpretation of findings in information-processing research. Specifically, in accordance with the 
hypothesis, researchers examining emotional-processing bias group their stimuli according to 
their relative affective valence. Hence, for instance, aggressive and fearful stimuli would be 
grouped as threatening (negative in valence; e.g., Bar-Haim et al., 2007; van Honk et al., 1998;). 
One reason this strategy can be considered problematic is outlined by proponents of the 
motivational direction hypothesis of emotional processing. 
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The motivational direction hypothesis posits that emotional information is not processed 
according to the valence of the stimulus, but rather that it is the tendency of the stimulus to 
provoke an approach- or avoidance-related response that determines its subsequent processing 
(Harmon-Jones, 2004). Evidence for this hypothesis comes from the observation that anger has 
the unique characteristic of being negative in valence while evoking approach motivation. 
Furthermore, findings demonstrate that anger is not processed in the right frontal brain region, 
but that processing of aggression occurs in the left frontal region (Pizzagalli, Sherwood, 
Henriques, & Davidson, 2005; van Honk & Schutter, 2006). There is a growing body of research 
that supports the motivational direction hypothesis (see, e.g., Heuer, Rinck, & Becker, 2007; van 
Honk et al., 1998, 2003; Pizzagalli et al., 2005; Putman, Erno, & van Honk, 2007). Pathology 
associated with bias towards approach-related stimuli (i.e., anger) may therefore produce 
different trends in attentional biases when presented with avoidance-related stimuli (i.e., fear). 
This is why it can be considered problematic to group aggressive and fearful stimuli together: 
they evoke responses in different motivational directions.    
Research into information-processing bias relies on a range of methodological paradigms. 
There is variation in the types of tasks used to elicit a processing bias; the types of stimuli 
presented; and the way in which stimuli are presented (see Bar-Haim et al., 2007). All of these 
design variations make cross-study comparison and evaluation difficult. Variation with regard to 
stimulus presentation may influence the validity of findings in emotional processing. This 
variation most often exists along these dimensions: the emotional stimulus is either presented 
under conditions that preclude conscious processing (unconscious/subliminal exposure), or under 
conditions that allow it to be consciously perceived (supraliminal exposure). 
The processing of emotional stimuli may yield different (or even opposite results) 
depending on whether those stimuli are presented subliminally or supraliminally (Bar-Haim et 
al., 2007; van Honk et al., 1998). One possible explanation for such confusing patterns of results 
is this: It is possible that participants are able to exert conscious control over task performance in 
emotional-processing paradigms. Under the motivational direction hypothesis, high levels of 
anxiety are associated with attentional bias toward fearful stimuli and an avoidance of angry and 
happy stimuli. In subliminal exposure paradigms, these trends would remain as expected. 
However, in supraliminal exposure paradigms, anxious participants may consciously control task 
performance through avoidance of fearful stimuli, and increased vigilance for angry and happy 
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stimuli (Mogg, Bradley, De Bono, & Painter, 1997; Williams, Mathews, & McLeod, 1996). This 
latter response would serve to direct attention away from the fearful stimuli, attenuating the 
threat value of the stimulus, and thereby reducing anxiety. Furthermore, conscious control 
appears to be more likely in non-clinical, high anxiety, populations compared to clinically 
anxious individuals (Williams et al., 1996). Thus clinically anxious individuals show similar 
response bias in both subliminal and supraliminal tasks.    
The Object Relocation Task (Kessels, Postma, & de Haan, 1999) has been proposed as a 
viable alternative to tasks that utilize subliminal stimuli. Specifically, this task has been found to 
overcome the problem of conscious control on task performance (Putman et al., 2007; van Honk 
et al., 2003). The task consists of sets of eight faces on a grid or blank background, displayed on 
a computer monitor. The sets contain four neutral faces each along with four emotional faces 
(i.e., faces showing emotional expressions of happiness, fear, anger, etc.). After viewing the 
faces, the display is emptied, and the faces reappear above the display grid / background in 
random order. Participants then have to move the faces using a computer mouse to their original 
positions on the screen. The task thus assesses spatial memory, because participants have to 
remember where in the computerized space the faces were originally. In light of their findings, 
Van Honk et al. (2003) suggest, following the motivational direction hypothesis, that because 
individuals high in anxiety possess a processing bias that would lead them to avoid angry and 
happy faces, it is likely that their spatial memory performance for these faces would be impaired. 
Hence, the task produces similar results to what would be expected from subliminal tasks 
(Putman et al., 2007; van Honk et al., 2003; van Honk & Schutter, 2006), namely, elevated levels 
of stress or anxiety are associated with bias towards fearful/avoidance-related stimuli and 
avoidance of approach-related stimuli (i.e., happy and angry faces). Evidence therefore suggests 
the Object Relocation Task for emotional faces is effective in overcoming the problems of 
conscious control in information processing observed in non-clinical high anxiety individuals.  
Studies using the object relocation task to study emotional processing bias have produced 
results that are fairly consistent with the trends suggested by the motivational direction 
hypothesis. In a study using basal levels of salivary cortisol as indices of stress and low mood 
and measuring performance on the object relocation task (presenting only happy, angry and 
neutral faces), van Honk et al. (2003) found that increased levels of cortisol were significantly 
positively associated with increased avoidance of happy facial expressions. They also found a 
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similar relationship for angry faces, although this trend only neared statistical significance. In 
another study using the object relocation paradigm, van Honk and Schutter (2006) found that 
processing of anger was significantly reduced after repeated transcranial magnetic stimulation 
(rTMS) deactivation of the left PFC, supporting the hypothesis that left PFC would decrease the 
processing of anger relative to deactivation of the right PFC by rTMS.  
The motivational direction hypothesis bears almost identical features to Gray’s BIS/BAS 
model of personality. Most notably, both differentiate individual traits along an approach-
avoidance dichotomy. The conceptual congruence between the theories was supported by a study 
examining their relationship using a subliminal/supraliminal emotional Stroop task. The authors 
found performance on the BAS items of the scale predicted response vigilance to angry faces, 
while measures of social anxiety significantly predicted avoidance of angry faces. BIS was found 
to correlate negatively with bias for angry faces in both the subliminal and supraliminal exposure 
conditions however the authors could not confirm the significance of these results (Putman, 
Hermanus, & van Honk, 2004).   
Because adults with a history of childhood trauma are regularly found to be high in 
neuroticism and have been found to be at risk for higher BIS, they are likely to demonstrate 
information-processing bias towards fear-provoking stimuli. In a recent study examining 
emotional Stroop performance in psychosomatic inpatients, Wingenfeld et al. (2011) showed that 
a history of childhood trauma was the best predictor of mean reaction time in all three word 
types used in the Stroop task. The authors only state that the words were neutral, negative, and 
symptom-related, but provide no specific indication of what the words were. These results 
suggest some evidence for an emotional-processing bias in individuals with a history of 
childhood trauma. However, some caution is warranted. The study used the Stroop color naming 
task, and previous research has noted that some degree of conscious control is possible with this 
task; hence, results may not be an accurate reflection of actual response bias. In addition, the 
authors did not specify or give any indication of what the motivational direction of the negative 
stimulus words were (i.e., anger/approach or fear/avoidance). 
In summary, the preceding discussion argued that traumatic experiences in childhood 
predisposes the maturing brain to alterations that are associated with increased risk of developing 
maladaptive personality traits in adult life. These traits signify enhanced responsiveness to 
stressors because of increased levels of anxiety and neuroticism within the adult survivor of 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
20 
 
childhood trauma. Furthermore, anxiety and neuroticism appear to be associated with increased 
BIS activation, which is also observed in adults with a history of early adversity. Finally, BIS 
sensitivity appears to influence the way in which emotional information is processed and in 
childhood trauma victims, in line with the motivational direction hypothesis, this bias appears to 
favor fear-provoking avoidance stimuli.  
The current study investigates whether increased BIS sensitivity will be observed in a 
sample of adults who have suffered traumatic childhoods and whether those adults will 
demonstrate similar information processing biases as those outlined in the literature reviewed 
above. A final objective of the current study is to establish whether it is possible to alleviate 
information processing bias for fear-provoking stimuli in the Trauma sample by administering 
the mu-opioid agonist buprenorphine during an Object Relocation Task. In order to understand 
why this effect may be expected the following part of the introduction will outline the 
neurophysiology of the stress response, which will introduce key brain regions and 
neurochemical processes that are implicated in mu-opioid activity. Research into the stress 
response has largely focused on PTSD and its associated symptoms. However, since childhood 
trauma does not always result in PTSD, findings related to PTSD should tentatively be extended 
to neurodevelopment following childhood trauma. 
 
Neurophysiology of the Stress Response  
According to the DSM-IV-TR (APA, 2000), PTSD consists of three primary symptom 
clusters: re-experiencing the trauma, avoidance of trauma-related external and internal cues, and 
hyperarousal/hypervigilance. Neurobiological models suggest that these three groups of 
symptoms result from prolonged physiological reactivity to traumatic stress that causes the 
physiological stress system to be overwhelmed (see, e.g., Weber & Reynolds, 2004). 
Specifically, these models suggest that an aversive stimulus causes hyperarousal of the stress 
system, leading to the flooding of the particular brain regions by the neurochemical constituents 
that help activate and regulate this system’s various responses. The result is dysregulation and 
structural alteration within the various brain regions associated with managing reactions to stress. 
These regions include the PFC, the amygdala, the hippocampus, the dorsal raphe nucleus, and 
the locus coeruleus. Three neurotransmitter / neurohormone systems have also been identified as 
playing an important role in mediating the stress responses: (a) the noradrenergic system, (b) the 
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serotonergic system, and the (c) hypothalamic-pituitary-adrenal (HPA) axis (Vasterling & 
Brewin, 2005). 
The locus coeruleus (LC) contains the majority of the brain’s noradrenergic cell bodies 
(Zigmond, Finlay, & Sved, 1995). When activated, these nuclei trigger a state of arousal in the 
organism, directing attention, increasing vigilance and alertness, and mediating cardiovascular 
responses to threat-provoking stimuli (Aston-Jones, Raikowski, Kubiak, & Alexinsky, 1994). 
Diverse afferent inputs in noradrenergic neurons facilitate the processing of relevant sensory 
information, while its large efferent network facilitates anxiety and fear-related skeletomotor, 
cardiovascular, neuroendocrine, and cognitive responses. Stimulation of the LC manifests in 
fear-related behavioural responses and increased NE release throughout the brain in regions such 
as the amygdala, hippocampus, hypothalamus, and PFC. These brain regions are associated with 
the perception, evaluation, remembering, and response to fear-inducing stimuli (Zigmond et al., 
1995). In states of extreme arousal, such as when confronted with severe stress, these regions are 
overwhelmed with NE, leading to impairment of their functioning (Arnsten, 2000; Birnbaum, 
Gobeske, Auerbach, Taylor, & Arnsten, 1999). 
After the organism is exposed to a stressor, the PFC (and, in particular, the orbitofrontal 
cortex), amygdala, and the hippocampus are further subjected to the effects of serotonin, which 
is released by the serotonergic system in response to that stressor. The serotonergic system is 
mediated by the raphe nuclei of the brainstem, which contain the majority of cell bodies 
responsible for the release of serotonin (Bremner et al., 2003; Nestler, Hyman, & Malenka, 2001; 
Koenen et al., 2001). 
Glucocorticoids are another important neuromodulator in the physiological stress 
response. Their release is regulated by the hypothalamic-pituitary-adrenal (HPA) axis. The HPA 
axis is a closed-loop system that activates and inhibits its own response. Under conditions of 
traumatic stress, the system’s regulatory mechanism fails to inhibit the production of 
glucocorticoids, causing an excess amount to be released into the brain (Bowman, 2005). 
Specifically, the HPA axis is a closed-loop neurocircuit controlled by a regulatory set of 
afferents, mostly the neurons in the paraventricular region of the hypothalamus. When the brain 
recognizes a stressful event or stimulus, these neurons secrete corticotrophin-releasing hormone 
(CRF). CRF stimulates the anterior pituitary gland to release adrenocorticotrophic hormone 
(ACTH), which then stimulates the adrenal gland to secrete glucocorticoids. The secretion of 
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glucocorticoids regulates the entire HPA axis by providing negative feedback to stop further 
CRF and ACTH release (Bowman, 2005). Increasing levels of glucocorticoids have been shown 
to disrupt the functioning of the PFC (Roozendaal, McReynolds, & McGaugh, 2004) and the 
hippocampus (Het, Ramlow, & Wolf, 2005; Kim & Diamond, 2002). 
These findings demonstrate the complexity of the mammalian stress response: a system 
of interconnected brain structures (e.g., PFC, amygdala, LC, dorsal raphe nuclei, HPA axis, etc.) 
that communicate via specific hormones and monoamines / indolamines (e.g., NE, serotonin, 
GC, etc.) in response to threatening stimuli. The system increases the state of arousal and 
prepares the individual to react behaviourally and cognitively to stressors. However, intense/ 
repetitive / prolonged activation of this system may cause neurobiological alterations in the brain 
structures that mediate the stress response. These structures are outlined below, and represent 
important components of the pathological stress response observed in individuals with elevated 
levels of anxiety such as in adults with a history of childhood trauma. Furthermore, these 
structures represent the neuroanatomical components upon which the mu-opioid agonist 
buprenorphine exerts its unique pharmacological properties (described later). 
Neurological correlates of pathological stress responses. Prolonged hyperarousal leads 
to damage of brain regions responsible for the stress response that may lead to dysregulation of 
stress responsivity, which in turn is associated with elevated levels of anxiety (Perry et al., 1995; 
Teicher et al., 2003; Weber & Reynolds, 2004). As noted above, these regions include the PFC, 
amygdala, and the hippocampus. For the purposes of this study, the focus will be mainly on the 
PFC and the amygdala, for the following reasons: The PFC has an inverse relationship with the 
amygdala, providing an inhibitory function to the negative affective responses of the amygdala 
(Kim & Diamond, 2002). In individuals who have experienced traumatic stressors, this action is 
reversed, allowing the amygdala to create a state of fear-induced hyperarousal (Liberzon et al., 
2002). In addition, these structures bare further relevance to this study since it appears that mu-
opioids may reduce response bias associated with elevated anxiety through its actions within the 
PFC and amygdala (Panksepp, 2003). 
Prefrontal cortex. Glucocorticoids and catecholamines have been found to optimize the 
functioning in the amygdala, but they have an opposite effect on the PFC, impairing the 
functioning of this brain region (Southwick et al., 2005). Optimal functioning of the PFC is 
critical to success on cognitive tasks such as planning, guiding, and organizing behaviour 
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(Goldman-Rakic, 1987). Furthermore, moderate levels of catecholamines are vital to the working 
memory function of the PFC, but high levels of catecholamines and glucocorticoids are 
associated with impaired functioning in this region (Arnsten, 2000). It is therefore notable that 
exposure to even mild stressors brings about high levels of catecholamine release in the PFC 
(Goldstein, Rasmussan, Bunney, & Roth, 1996). 
The excessive release of NE under conditions of severe stress creates a chemical context 
that suppresses the functions of the PFC. The functional effects of NE on PFC are mediated by 
postsynaptic alpha1, beta1, and alpha2A receptors. Specifically, at moderate levels NE binds with 
alpha2A receptors, which improve PFC functioning, thus acting as a protecting agent. However, 
high levels of NE under high stress conditions, activates alpha1 receptors, thus causing PFC 
dysfunction (Southwick et al., 2005). Interestingly, it appears that individuals with PTSD have 
reduced levels of alpha2-adrenergic receptor numbers compared to healthy controls, as well as 
more NE excretion as measured over a 24-hour period (Perry, 1994). 
Taken together, through the actions of NE, severe stress creates a depressed environment 
within the PFC, while at the same time stimulating amygdala activity. The implications of a 
hypoactive PFC together with a hyperactive amygdala are addressed below. For the moment, 
however, we focus on the fact that NE is not the only catecholamine acting on the PFC. 
It appears that the negative effects of catecholamines and glucocorticoids on the working 
memory function of the PFC can be reproduced by dopamine D1 agonist infusion into the PFC 
and inhibited by dopamine D1 receptor blockade (Southwick et al., 2005). Dopamine (DA) is an 
important stress neuromodulator. Following exposure to extreme stress, the resultant release of 
DA in the PFC overstimulates this region, leading to reduced responsiveness, and thereby 
diminishing the functioning of the PFC. The resulting dysfunction in the PFC is associated with 
the symptoms of hypervigilance and paranoia in PTSD (Weber & Reynolds, 2004). The 
pathology underlying the PFC is also related to the intrusive symptoms experienced in PTSD. 
Hypoactivation of the PFC leads to an inability to suppress involuntary thoughts and direct 
attention, presumably leading to intrusive symptoms (Kanagaratnam & Abjormsen, 2007). 
Importantly, Teicher et al. (2003) state that the PFC may be especially vulnerable to the 
effects of trauma in childhood. The authors believe the vulnerability of the young PFC to 
traumatic stressors stem from this regions’ relatively high density of glucocorticoid receptors 
coupled with its delayed ontogeny. 
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 As mentioned above, the effects of severe stressors subject the PFC to a state of 
hypoactivity. This is a significant component of the exaggerated stress response seen in 
individuals with heightened levels of anxiety as the PFC is thought to play an inhibitory role on 
fearful responses (Liberzon et al., 2002). An additional component to the hypersensitive stress 
response in high anxiety individuals is the anterior cingulate cortex (ACC) found within the 
medial prefrontal cortex (mPFC). The ACC is associated with the generation of the affective 
experience of pain. Findings show that activation of this region is positively associated with 
feelings of social distress and self-induced sadness (Eisenberger, Lieberman, & Williams, 2003; 
Mayberg, 1997). Trauma related alterations in this region are associated with decreased 
inhibition of ACC-induced emotional reactivity (Liberzon, et al., 2007).   
Amygdala. The amygdala is a brain region crucially involved in both the detection and 
expression of fear (Davis, 1992). It is connected to the hypothalamus and brainstem nuclei that 
mediate fear responses, including freezing behaviours, alterations in heart rate and blood 
pressure, sweat gland activity, and release of stress hormones. Catecholamines play a key role in 
the amygdala, enabling encoding, consolidation and retrieval of memory for events and stimuli 
that are arousing, stressful, and fear provoking (Southwick et al., 2005). 
Optimal functioning of the amygdala occurs during stress exposure. This is because, 
during such exposure, the neurochemical environment within the amygdala consists mainly of 
high levels of catecholamines and glucocorticoids, which assists in the consolidation of 
emotionally relevant memories and in fear conditioning (Southwick et al., 2005). 
Increased levels of NE are observed in chronically stressed organisms. Subsequent 
arousal would then exaggerate the levels of NE and glucocorticoids in the amygdala and PFC. 
While this would create an optimal environment in the amygdala, high levels of NE in the human 
PFC would likely impair executive functioning, giving greater control to the amygdala to govern 
behaviour and physiological reaction. The result of this sequence of events would be increased 
fear-related behaviour (Davis, 1992), such as an exaggerated startle response, increased fear 
conditioning, increased vigilance, insomnia, impulsivity, and so on. 
Greater left amygdala responses to traumatic versus neutral cues have been observed in 
PTSD subjects compared to controls, while it appears that symptom severity can be correlated 
with regional cerebral blood flow (rCBF; indicating increased metabolic activity) within the right 
amygdala in PTSD groups (Shin et al., 2004). rCBF also appears to correlate positively with self-
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reported anxiety in PTSD participants (Pissiota et al., 2002). Etkin and Wager (2007) conducted 
a meta-analysis of imaging studies examining functional neurobiological deficits in PTSD, social 
anxiety disorder, and specific phobias and found that hyperactivity of the amygdala was a 
consistent symptom across all three disorders.  
The experience of childhood has also been suggested to induce similar alterations in the 
activity of the amygdala. Specifically, neurodevelopmental changes in the amygdala subsequent 
to the experience of a traumatic event are associated with decreases in inhibition of amygdala 
activation, resulting in elevated fearfulness and anxiety in later life (Teicher et al., 2002, 2003).  
In summary, studies investigating the structure and functioning of brain pathology 
associated with PTSD and other anxiety disorders have found varying degrees of 
abnormalities/deficiencies in the amygdala and the PFC. The evidence suggests that in 
individuals with elevated anxiety, the amygdala displays heightened activation, while the PFC 
displays an opposite tendency to decrease in activation; hence, one observes an inverse 
relationship between the amygdala and the PFC. This pattern of activation between the amygdala 
and the PFC helps explain the increased incidence of anxiety and neuroticism in adults who have 
suffered childhood adversity. Panksepp (2003) hypothesizes that the experience of negative 
affective states such as fear may be alleviated by the administration of exogenous mu-opioid 
agonists. If this assertion is correct, the administration of exogenous mu-opioid agonists to high 
anxiety individuals may result in decreased negative affect and, by extension, decrease the fear 
response in this population possibly leading to the attenuation of avoidance related response bias. 
The possible mechanisms underlying this process are discussed below. 
 
mu-Opioids 
The mu-opioid system comprises three classes of endogenous opioid peptides: 
endorphins, enkephalins, and dynorphins. These opioids bind with three families of opioid 
receptor: mu, kappa, and delta. Mu-opioid receptors are responsible for the regulation of brain 
regions and neurotransmitter systems that mediate the processing of emotional information, 
stress responses, and reward (Mansour, Fox, Akil, & Watson, 1995). These regions include, the 
ACC, PFC, insular cortex (IC), amygdala, thalamus, and basal ganglia (Firestone et al, 1996; 
Schlaepfer et al., 1998; Wagner et al., 2001; Zubieta et al., 2003). 
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mu-Opioids have been found to have analgesic effects, through inhibiting pain induced 
neuronal activity (Casey et al., 2000). Pain relief is associated with increased concentrations of 
mu-opioid receptors in regions including ACC, IC, PFC, thalamus, and basal ganglia (Apkarian 
et al., 2005; Jones et al., 1999). Furthermore, Zubieta et al. (2001) found reductions in mu-opioid 
receptor availability in the ACC, PFC, IC, thalamus, ventral basal ganglia, amygdala, and 
periaqueductal grey were observed in patients with sustained muscular pain. Reductions in mu-
opioid receptor availability suggests decreased activation of this neurotransmitter system in the 
relative brain regions. The authors also found a correlation between the mu-opioid 
neurotransmitter system and the suppression of sensory and affective qualities of pain. These 
findings indicate that the analgesic properties of mu-opioids work through very similar brain 
systems as those altered through the experience of traumatic stressors (i.e., PFC, ACC, 
amygdala). In addition, the analgesic properties of mu-opioids involve both the suppression of 
physical pain and the affective component of pain. 
The opioid system is essential in the activation of pleasurable, and the inhibition of 
negative, emotional states (Nelson & Panksepp, 1998; Panksepp, 2003). As mentioned earlier, 
mu-opioid receptors are concentrated in the ACC. Increased activation of this region is 
associated with both psychological pain and the experience of social distress. mu-Opioid 
neurotransmission in this region is associated with inhibition of this kind of negative emotional 
reactivity (Liberzon et al., 2007). Furthermore, greater levels of activity in the ACC are 
associated with decreased activity of the PFC, and visa versa, suggesting an inhibitory role of the 
PFC on the ACC (Panksepp, 2003). 
Liberzon et al. (2002) found that increased mu-opioid availability in three areas of the 
amygdala was associated with a reduction in the neural intensity of emotional response to 
aversive emotional pictorial stimuli (e.g., mutilated faces, dead bodies, etc.). The authors found a 
negative correlation between rCBF in these regions and mu-opioid availability at baseline. These 
observations suggest an inhibitory role of the mu-opioid system in response to aversive stimuli in 
the amygdala. These authors also found a negative correlation in rCBF between the mPFC and 
the left amygdala, suggesting a possible inhibitory role of the PFC on amygdala activation. 
Furthermore, Liberzon et al. (2007) assessed two groups of combat veterans (PTSD and non-
PTSD with combat exposure) and a matched control group (without prior trauma exposure). In 
both the trauma-exposed groups they found that in regions where mu-opioid activity causes 
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inhibition of the amygdala (rostral component of the extended amygdala) there were less mu-
opioid receptors compared to those same regions in the control groups. Hence, mu-opioid 
agonists released in this region would have limited receptors to bind to, and consequently exert 
less of an effect. In the caudal amygdala on the other hand, where direct mu-opioid activity 
increases activation of the amygdala, there was no decrease of receptors in the PTSD group, 
leaving them vulnerable to enhanced amygdala activity and a focus on negative emotion 
(Liberzon et al., 2007). 
In summary, mu-opioids are concentrated in similar brain regions as those which are 
involved in the stress response (e.g., PFC, ACC, amygdala, etc.). Within these regions mu-
opioids are responsible for the inhibition of negative affective responses. Decreases of mu-opioid 
receptor availability within the ACC are associated with increased social distress, while similar 
mu-opioid dysregulation within the amygdala is associated with an increased fear response. 
These abnormalities in ACC and amygdala mu-opioid receptor availability have been observed 
in victims of trauma and possibly contribute to the elevated levels of anxiety and hypersensitive 
stress response observed in this population of individuals. Finally, a lack of mu-opioid mediated 
inhibition of the ACC and the amygdala is associated with decreased PFC activation. 
Abnormalities in mu-opioid mediated neurotransmission in victims of trauma may therefore 
contribute to the hyperactivation of the amygdala and hypoactivation of the PFC observed in this 
population. 
Given the findings by Liberzon et al. (2007), reduced mu-opioid regulation may also be 
observed for adults with a history of childhood trauma. Administration of exogenous mu-opioid 
agonists, as happened in this study, could compensate for the shortage of mu-opioid mediated 
neurotransmission inducing anxiolytic effects within trauma-exposed individuals. The present 
study examines these effects in relation to performance on an Object Relocation task for 
emotional faces. It is hypothesised here that administration of an exogenous mu-opioid agonist 
will have the effect of reducing avoidance-related response bias in adults with a history of 
childhood trauma. 
mu-Opioid agonist buprenorphine. Buprenorphine is the mu-opioid agonist used in the 
present study. It has high affinity (i.e., strong interaction with receptors) for mu-opioid receptors 
and full agonistic (i.e., its analgesic effects are dose dependent, exhibits no ceiling effects, and 
can reach 100% occupancy at receptors) properties at these receptor sites (Ding & Zaffa, 2009; 
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Pergolizzi et al., 2010; Raffa & Ding, 2007).While buprenorphine has no ceiling effect with 
regard to its analgesic properties, there is a ceiling effect for respiratory depression (unlike other 
mu-opioid full agonists, e.g., morphine), which reduces the likelihood of this potentially fatal 
event from occurring and therefore contributing to its’ safety in clinical use. In addition, 
buprenorphine is considered safe to use in combination with other opioids (e.g., morphine), and 
is considered a safe and effective option for the treatment of chronic pain conditions (Pergolizzi 
et al., 2010).        
 
Conclusion 
Childhood trauma has been associated with increased vulnerability for the development 
of a psychiatric disorder in later life including a range of personality disorders. Neuroticism and 
heightened BIS activation are examples of personality traits that are associated with adult 
survivors of childhood trauma. These traits are related with elevated levels of anxiety in this 
population. Increased anxiety predisposes the victim to a response bias for fear-related stimuli, 
and avoidance of approach-related stimuli. Furthermore, it may be possible to attenuate that bias 
through the administration of exogenous mu-opioids. mu-Opioids exert their effects on similar 
brain regions as those that mediate the stress response, and since adults with a history of early 
adversity have possibly been subjected to extreme stressors in childhood, those regions may be 
particularly susceptible to the effects of the drug.  
 
Specific Objectives of the Current Study 
The neurobiological consequences that occur after experiencing a traumatic event, 
whether in childhood or later in adult life, are complex and multi-faceted. The experience of 
severe stress results in a range of neurophysiological changes that predisposes the victim to a 
host of behavioural, cognitive, and emotional distortions that may lead to disorder. These 
changes have only recently been investigated in those with a history of early adversity, including 
childhood trauma. The aim of this study was to contribute to the existing literature describing the 
relationship between adverse childhood experience and adult personality traits, and associated 
bias in information processing. A further contribution of the current study involves measuring 
the possible attenuating effects of mu-opioid agonist buprenorphine on the information-
processing bias observed in individuals with elevated levels of anxiety.  
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Trauma status in the current study was determined by participants’ self-reports on the 
Childhood Trauma Questionnaire – Short Form (CTQ-SF; Bernstein et al., 2003). Specifically, 
those individuals who obtained a score in the moderate to severe range on at least one CTQ-SF 
subscale constituted the Trauma group. Individuals with either (a) scores in the minimal range on 
all CTQ-SF subscales, or (b) a score in the low to moderate range on only one CTQ-SF subscale 
constituted the Control group. The design of the study allowed, as a preliminary step, 
investigation of the psychometric properties of the CTQ-SF. Specifically, the test-retest 
reliability of the CTQ-SF was examined over three separate administrations, spanning at least 1 
week between the first and second administrations, and at least 1 week between the second and 
third administrations.    
Following this preliminary step, I tested the following specific hypotheses, all of which 
emerged from the literature reviewed above: 
1. With regard to BIS/BAS sensitivity, adults who have experienced childhood trauma 
will have heightened BIS activation, given increased levels of anxiety and 
neuroticism observed in this population, compared to healthy matched controls. 
Increased BIS activity will be reflected in higher scores on the BIS index of the 
BIS/BAS scale (Carver & White, 1994). I predicted that there would be no significant 
differences between the Trauma and Control groups in terms of BAS sensitivity 
because elevated levels of anxiety, such as those associated with a history of 
childhood trauma, are not related to BAS activation. 
2. On the Object Relocation Task, adults with a history of childhood trauma will 
demonstrate an information-processing bias for threat-related stimuli and avoidance 
of approach-related stimuli. These biases will be reflected by smaller error scores, 
compared to healthy matched controls, in the relocation of fearful faces to their 
original locations, and larger error scores, compared to the same controls, in the 
relocation of angry and happy faces to their original locations.   
3. Attenuating effects of buprenorphine on performance for the fearful faces condition 
will be observed for the Trauma group, but not the controls. Thus, error scores of the 
Trauma group for threat-related stimuli will increase subsequent to buprenorphine 
administration, yielding significant within-group differences for the Trauma 
participants on their performance between the medication and placebo conditions. 
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METHODS 
Participants recruited into this study were part of a larger research programme examining 
the effects of buprenorphine on affective experience, social behaviour, and neural circuits in 
individuals with and without a history of childhood trauma. Potential participants underwent 
rigorous screening procedures that were part of multiple phases of data collection. These phases 
consisted of the following: First, an initial online questionnaire attracted a large number of 
potential participants (N = 856). This screening survey was followed by an in-person screening 
interview and testing session, which helped narrow down the list of potential participants until it 
was possible to have two clearly defined sample groups, namely, a Trauma and a Non-Trauma 
(i.e., control) group. Once these groups were established participants within each group 
underwent two phases of testing (Behavioural 1 and Behavioural 2), during which multiple 
questionnaires were delivered and various neuropsychological tests administered. The mu-opioid 
buprenorphine was administered to each participant during only one of these sessions, while in 
the other session participants received a placebo. Participants were not informed about whether 
they had received the drug or the placebo.  In addition, the researchers involved in data collection 
were blind to the medication condition. The final phases of the larger research project consisted 
of two neuroimaging sessions, one under medication and one under placebo, where participants 
underwent fMRI scanning to investigate possible functional effects of buprenorphine. The 
phases/sessions relevant to the current study, and the measurement instruments associated with 
each, are outlined below. 
 
Participants and Procedure 
Online screening phase. A total of 856 adults between the ages of 18 and 28, primarily 
from the University of Cape Town’s student population and surrounding community, were 
recruited into the larger study of childhood trauma and its consequences. Posters advertising the 
research were placed in and around most departments on campus, as well as in student residences 
and on public notice boards. The posters directed interested individuals to an online survey that 
acted as the initial screening procedure. 
Individuals who completed the survey were excluded from further participation in the 
research reported here if their self-rating on the Edinburgh Handedness Scale (Oldfield, 1971) 
suggested that they were primarily left-handed. Only right-handed participants were included in the 
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study in order to eliminate the possibility of individual differences in cerebral functional 
organization. Thirty-nine individuals who completed the survey were excluded from further 
participation on this basis. 
Additionally, individuals who completed the survey were excluded from further 
participation if they reported on the List of Threatening Experiences (LTE; Brugha & Cragg, 
1990) having faced a number of distressing and potentially traumatic events within the previous 
6 months. This sampling criterion was put in place because the study focused only on individuals 
with a history of childhood trauma. Eleven individuals who completed the survey were excluded 
from further participation on this basis. 
Individuals who completed the survey but who obtained high scores on the 
Minimalization/Denial subscale of the Childhood Trauma Questionnaire – Short Form (CTQ-
SF; Bernstein et al., 2003; Appendix B) were excluded from further participation. This sampling 
criterion was put in place because the CTQ-SF was the only measure of childhood trauma used 
in this study, and therefore it was essential to exclude all questionable CTQ profiles. Twenty-
three individuals who completed the survey were excluded from further participation on this 
basis. 
Finally, individuals who completed the survey but who obtained a low to moderate score 
on two or more subscales of the CTQ-SF, and did not have at least one moderate to severe score 
on at least one CTQ-SF subscale, were excluded from further participation. Six hundred and 
seventy individuals who completed the survey were excluded from further participation on this 
basis. This latter sampling criterion was put in place to help ensure that we could establish two 
clearly defined groups: 
1. A Control group, consisting of individuals with either (a) scores in the minimal 
range on all CTQ-SF subscales, or (b) a score in the low to moderate range on 
only one CTQ-SF subscale. After application of the screening criteria described 
above, this group consisted of 68 participants. 
2. A Trauma group, consisting of individuals with a score in the moderate to severe 
range on at least one CTQ-SF subscale. After application of the screening criteria 
described above, this group consisted of 45 participants. 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
32 
 
In summary, after analyzing the data derived from the online survey, 113 of the 856 
individuals who had completed the survey were deemed eligible to continue participation in the 
research reported here. These individuals were contacted telephonically for additional screening. 
At this stage of the study, 4 individuals either declined to participate further1 or were 
unreachable. 
Telephonic screening phase. The remaining 109 individuals were contacted via 
telephone in order to conduct a clinical interview that screened for the presence of the following: 
a history of substance abuse; a history of any DSM Axis I psychiatric disorder or Axis II 
personality disorder; a history of neurological disease; and current psychoactive prescription 
medication. The presence of any one of these led to the individual’s exclusion from further 
participation. The reasons these exclusion criteria were set in place include the fact that previous 
studies have shown that some prescription medications (e.g., selective serotonin reuptake 
inhibitors), excessive substance abuse, and comorbid psychiatric disorders may influence brain 
size and functionality (Jatzko et al., 2006; Smith, 2005). The clinical interview led to the 
exclusion of 31 individuals from further participation. Nine participants met the diagnostic 
criteria for depression, three for dysthymia, 12 for alcohol and substance abuse, and seven for 
panic disorder, general anxiety disorder, and social phobia. After telephonic screening, nine more 
individuals chose to withdraw from the study.2 The remaining 69 individuals were invited for an 
in-person interview and testing session. 
The in-person interview and testing session. This interview and testing session was 
conducted in the Applied Cognitive Science and Experimental Neuropsychology Team 
(ACSENT) laboratory in the UCT Department of Psychology. The participants were asked to fill 
out another CTQ-SF, as well as a BIS/BAS questionnaire (Behavioural Inhibition System / 
Behavioural Activation System; Carver & White, 1994; Appendix C). Those with CTQ-SF 
scores (see Appendix A) that were inconsistent across the online and in-person administrations 
were excluded from further participation, i.e., if their trauma classification differed on the two 
administrations, or if either were rated as of questionable validity, using the validity items built 
into the CTQ-SF, then those participants were not included. Furthermore, one of the scores per 
                                                 
1These participants declined due to personal reasons, including work and course commitments. 
  
2These individuals declined further participation due to personal reasons, including work and course 
commitments. 
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person could be rated as displaying "some minimization/denial", though if both ratings did, then 
this was grounds for exclusion as well. On this basis, we excluded 25 participants (16 from the 
Control group and nine from the Trauma group). 
The BIS/BAS questionnaire was initially scheduled to be administered only during the 
first scan of the scanning phase of the larger research project. However, we subsequently 
administered the BIS/BAS at either the in-person interview or during the Behavioural 1 session 
because of time constraints during the scanning sessions. 
The behavioural testing sessions. At this point, 44 participants continued to undergo 
behavioural testing, which occurred over two sessions. The two behavioural sessions for each 
participant were scheduled with at least a 1-week interval inbetween. Mu-opioid agonist 
buprenorphine and placebo was administered in alternating sessions for each participant. 
Experimenters and participants were blind as to the drug schedule. Administration of the placebo 
and mu-opioid agonist buprenorphine occurred at the start of the session. Based on previous 
literature, we estimated that the drug would exert its’ strongest effect after approximately 90 
minutes (e.g., Walsh, Preston, Stitzer, Cone, & Bigelow, 1994). During that interval, participants 
were assessed on a range of tasks that were not related to the intervention of the drug. The 
BIS/BAS scales were administered during the first behavioral testing session within the 90 
minutes before the drug was digested. The object relocation task was administered within both 
behavioural sessions after the 90 minutes had elapsed. Once the 44 participants concluded 
behavioural testing, they continued into the fMRI stage of the larger research project.   
The scanning phase. In summary, then, 44 participants (20 who had experienced at least 
one moderate to severe childhood trauma but who did not carry a diagnosis of current PTSD, and 
24 healthy controls) remained eligible for the scanning phase of the larger study. Before either of 
the scans, participants completed their final CTQ-SF and BIS/BAS questionnaires. The BIS-BAS 
scales were administered during the testing phase of the first scan, while the CTQ-SF was 
administered during the testing phase of the second scan. The questionnaires were completed 
within 90 minutes after administration of either the placebo or buprenorphine (i.e., within the 
threshold before buprenorphine was to take effect). This procedure was followed in order to 
avoid any effect of the drug on completion of the questionnaire. 
To conclude, data from 38 participants were used in the analysis of the Object Relocation 
Task. Of those participants, BIS/BAS data were available for 36 participants, while 29 completed 
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all three CTQ-SF questionnaires (i.e., administered in the online survey, at the in-person 
interview, and at the second scanning session).  
 
Materials and Medication 
Buprenorphine. Participants in both the control and trauma groups were administered 0.2 
mg of the mu-opioid agonist buprenorphine and placebo (sublingual) in alternating sessions 
within both the behavioural and scanning parts of the study. The experimenters and participants 
were blind to the schedule of the drug. In addition, the medications were consumed at least 90 
minutes before commencement of the object relocation task, to ensure an optimal effect of the 
drug. 
Object Relocation Task. This is a computerized task that assessed memory for 
emotionally-laden faces presented on a screen. Participants received one practice trial each after 
which the actual task began and their performance was measured. Eight faces appeared on a 
screen, of which four were neutral faces and four were in either a state of anger, fear, or 
happiness. Only one emotion was on display within each trial. There were 12 trails in total (four 
trials for each of the three emotions). 
On each trial, the stimuli were presented on a gray background. After 30 s, this 
background was emptied, and the faces re-appeared above it in random order. The participant 
then had to move the faces to their original positions on the background using a computer mouse. 
The outcome variable here is deviation (in millimetres) between the participant’s 
indicated position for each face and its original position. Indices for memory/attentional bias 
were derived by subtracting performance on the angry/happy/fearful faces from performance on 
the neutral faces (similar analyses are described by Van Honk & Shutter, 2006). Figure 1 
represents a screen shot from the Object Relocation Task (neutral faces condition) used in the 
present study. 
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Figure 1. Screen shot of the Object Relocation Task in the neutral faces condition  
 
Childhood Trauma Questionnaire – Short Form (CTQ-SF). The CTQ-SF (Bernstein et 
al., 2003) is a retrospective self-administered instrument that was developed and validated as a 
rapid assessment screening tool for maltreatment histories in both clinical and non-clinical 
individuals. The CTQ-SF is a 28-item version of the original 70-item Childhood Trauma 
Questionnaire (CTQ; Bernstein & Fink, 1998; Bernstein et al., 1994), which also assesses early 
adversity. It contains five subscales, three assessing abuse (Emotional Abuse, Physical Abuse, 
and Sexual Abuse) and two assessing neglect (Emotional Neglect and Physical Neglect). 
Respondents are required to rate the extent to which they experienced different traumatic 
childhood events. Each subscale contains 5 question items; responses are recorded on a 5-point 
Likert-type scale, ranging from “never true” to “very often true”. The minimum score of 5 on a 
particular subscale indicates no history of abuse or neglect, while the maximum score of 25 
indicates an extreme history of abuse or neglect. The instrument also contains a three-item 
Minimization-Denial subscale to help detect false-negative trauma reports. 
The CTQ-SF has demonstrated good criterion-related validity when compared to 
therapists’ ratings of a group of psychiatrically referred patients, on whom corroborative data 
were available (Bernstein et al., 2003). Although the original CTQ showed excellent test-retest 
reliability over a 2-to 6-month interval (Bernstein et al., 1994), there are currently no data 
available for the test-retest reliability of the CTQ-SF. Filling this gap in the literature constitutes 
a major component of the current study. 
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 The CTQ-SF was suitable for the purpose of the current study as it is brief (it can be 
administered in only 5 minutes) and appropriate for use in the target population (Raudsepp, 
2006). The CTQ-SF has successfully been used to investigate childhood trauma in the South 
African context (Lochner et al., 2004).  
 Edinburgh Handedness Inventory. This instrument is a self-report measure of hand 
preference (Oldfield, 1971). The respondent is required to indicate which hand he/she would be 
most likely to use to complete 10 common household or sport-related actions that require the use 
of one hand to complete (e.g., brushing ones teeth, or writing). This instrument has high internal 
consistency and has been shown to be useful for screening purposes, especially where large 
populations are involved and where a standard of comparison in neuropsychological work is 
needed. It is also a reliable screening tool in populations that differ across gender, socio-
economic, and cultural lines (Oldfield, 1971; Williams, 1991). 
List of Threatening Experiences (LTE). The LTE (Brugha & Cragg, 1990) is a self-
report measure designed to identify the presence of stressful life experiences. The 12 items on 
the instrument relate to events such as serious illness, death of close friends or family members, 
and major financial crises. Respondents are required to highlight whether they have experienced 
any of these events either in the past 6 months or more than 6 months ago. The LTE was chosen 
because it is relatively quick to administer, requiring only 5-10 minutes to complete. It has also 
demonstrated good test-retest reliability and concurrent validity (Humke & Radnitz, 2005). This 
instrument has proven useful in the assessment of traumatic events in South African populations 
(Seedat et al., 2004).  
Behavioral Inhibition System/Behavioral Approach System (BIS/BAS) Scales. The 
BIS/BAS (Carver & White, 1994) is a self-report scale that measures sensitivity in the activation 
of two general motivational systems that are theorized to underlie behavior and affect: a 
behavioral inhibition system (BIS) and a behavioral approach/activation system (BAS). The 
scales consist of 20 question items scored on 4-point Likert scales. The BIS scale includes 7 
items that assess sensitivity to external cues of punishment, fear, and anxiety-provoking events 
(e.g., “I feel worried when I think I have done poorly at something”). The BAS scale includes 13 
items, which are divided across three subscales. The subscales are Drive (4 items, e.g., “I go out 
of my way to get things I want”), Fun Seeking (4 items, e.g., “I crave excitement and new 
sensations”), and Reward Responsiveness (5 items, e.g., “When I get something I want, I feel 
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excited and energized”). Higher scores on each of the items indicate greater sensitivity of the 
system being measured. The BIS/BAS scales have demonstrated good test-retest reliability, 
internal consistency and a valid factor structure (Carver & White, 1994; Jorm et al., 1999). 
 
Ethical Considerations 
Ethical permission for the study was granted by the Research Ethics Committee of the 
University of Cape Town (UCT) Faculty of Health Sciences, by the Research Ethics Committee 
of the UCT Department of Psychology, and by the Stellenbosch committee for clinical trials 
register.  
Participants received monetary compensation at the end of the first and second scan. 
Upon conclusion of their involvement in the study (i.e., after the second scan) participants were 
also provided with a compact disc containing 3 dimensional fMRI images of their brains. 
Consent forms (see Appendix D, E, F) were provided to and signed by all participants in the 
study. These forms guaranteed confidentiality and provided details of the study and ensured the 
safety of the medication to be administered. The information provided in the consent forms 
contained no specific aims of the study, to avoid bias in performance that such information may 
produce. The experimenters involved in the study were trained on administration of relevant 
questionnaires and procedures for drug administration.  
 
Data Analysis: Scoring procedures 
To fully understand the nature of the outcome variables presented in the analyses, 
descriptions of the scoring procedures for the three measures used in this study are described 
below. 
CTQ-SF and BIS/BAS scales. Similar procedures were used to score both of these 
questionnaires. Both scales consist of various subscales. Scores on each of the question items for 
these subscales were added together to produce, first, a score for that subscale and, then, a total 
score for the entire questionnaire. For both the CTQ-SF and the BIS/BAS, higher scores on each 
of the subscales means a higher presence of the trait/characteristic represented in that subscale.     
Conversion of scores for the object relocation task. The initial outcome of performance 
on the Object Relocation Task is the amount of deviation, in number of pixels, of each of the 
relocated faces from their original position on the computer screen to the position in which the 
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participant placed them. The software underlying the program produces a deviation score in 
pixels on both an X and Y axis of the computer monitor. Thus, for each face relocation there will 
initially be two scores, an “X-deviation-in-pixels” and a “Y-deviation-in-pixels”. Before 
producing an average deviation across both axes, the pixel deviation was converted manually 
into millimetres for both axis results. This was done by dividing the deviation in pixels by the 
resolution of the screen for the given axis (X or Y, depending on which axis the deviation score 
that was being converted lay) and multiplying that by height or width of the monitor depending 
on the relevant axis (Y = height; X = width) being converted. The result is deviation in 
millimetres upon one axis only. The conversion thus needs to be done for both X and Y 
deviation-in-pixel scores. Once scores for both axes were converted to millimetres, those scores 
were then averaged. This resulted in an average deviation in millimetres for each relocated face. 
This procedure was carried out for both the emotional faces and the neutral faces, across both the 
medication and the placebo conditions.   
Once the scores were converted, performance on the emotional faces was subtracted from 
performance on the neutral faces to produce an attentional bias score for each of the emotional 
face conditions. If the result was a negative score, that number would be converted to positive 
since the measure of interest was a unit of distance. This score represented the amount of error in 
distance the participant had produced in relocating the emotional face. Each participant received 
12 scores: four scores for performance on each of the emotions presented by the faces (happy, 
fear, and angry). These scores were then averaged across each of the emotions to produce an 
average performance for each emotional face condition. The 12 scores were thus reduced to three 
scores for each participant (one each for happy, fear, and angry). This analysis was carried out 
for both the medication condition and the placebo condition, resulting in a final tally of six 
scores per participant. 
 
Statistical Procedures 
 For all statistical analyses, descriptive statistics were explored first. This exploration 
allowed for an initial examination of the surface features of the variables under investigation 
(e.g., participant characteristics, possible group differences in performance, etc.). Examination of 
the descriptive statistics was also important because it allowed for the testing of assumptions that 
must be upheld before the relevant inferential statistics could be computed. 
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Between-groups comparison of demographic, clinical, and personality characteristics. 
In order to examine whether the Trauma and Control groups were matched according to key 
demographic variables, a series of one-tailed t-tests were conducted on all continuous variables, 
and a series of chi-square (χ2) analyses were conducted on all categorical variables. A series of 
one-tailed independent samples t-tests were also computed to investigate whether the two groups 
in the current study were significantly different in regard to key clinical and personality 
characteristics (i.e., scores on the BIS/BAS and CTQ-SF subscales). 
Test-retest reliability of the CTQ-SF. To explore the test-retest reliability of the CTQ-SF, 
Pearson’s product-moment correlation coefficients (r) were conducted on data from the three 
administrations of the CTQ-SF. These correlations were computed for all the subscales 
individually and for the total CTQ-SF score. 
Medication effects and performance on the Object Relocation Task. To investigate 
differences in attentional bias as measured by this task, and possible medication effects on task 
performance, a 2 x 6 repeated-measures factorial ANOVA was performed, taking into account 
the effects of multiple trials on task performance. 
For all analyses, the threshold for statistical significance was set at α = 0.05. All analyses 
were conducted using the software package Statistica version 9 (Statsoft, 2009). Effect size 
estimates were calculated and reported, where appropriate. 
  
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
40 
 
RESULTS 
 
Socio-Demographic Characteristics of the Sample 
As shown in Table 1, the Trauma and Control groups were well matched in terms of age 
and sex. There was some diversity in terms of the racial composition of the groups, however.  
 
Table 1  
Demographic Characteristics of the Current Sample (N = 38) 
Outcome variable 
Sample Trauma Control 
(n = 38) (n = 16) (n = 22) 
Age (in years) 22 (4.514) 22.062 (4.781) 21.955 (4.424) 
    
Sex (M:F) 19:19 8:8 11:11 
    
Race    
 % Black African 34 37.5 32 
 % White 34 18.75 45 
 % Coloured 24 25 23 
 % Asian 5 12.5 0 
  % Indian 3 6.25 0 
Note. For all the variables not presented as percentages or ratios, means are 
presented with standard deviations in parentheses. 
 
 Age. In order to assess for possible between-group differences in terms of age, a two 
tailed t-test was performed on the data. Levene’s test showed that the assumption of 
homogeneity of variance was upheld, F(1, 36) = 0.060, p = 0.807. A two-tailed t-test with pooled 
variance estimates indicated that there were no statistically significant between-group differences 
in terms of age, t(36) = 0.072, p = 0.943.  
 Sex. As shown in Table 1, there were exactly identical male to female ratios in the 
sample and within the Trauma and Control groups. Therefore, no additional inferential tests were 
necessary to confirm that there were no between-group differences in terms of sex distribution. 
 Race. A chi-square analysis investigated possible between-group differences in terms of 
race distribution. The results suggested that similar numbers of participants of different races 
were present in each of the two groups, χ2(4) = 6.164, p = 0.187. Interpretation of these results 
requires a degree of caution, however, as fewer than 80% of the data cells had frequencies 
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greater than 5, and the control group had no Asian or Indian participants, yielding data values of 
0 in those cells. 
 The results from the above analyses suggest the Trauma and Control groups were well 
matched for the demographic characteristics of age, sex, and race. With regard to another 
important demographic variable, level of education, all participants in this sample were members 
of the UCT student population, and therefore it is probable that there were no statistically 
significant between-group differences in this regard. 
 
Clinical Characteristics of the Sample 
 All participants completed the CTQ-SF on three separate occasions, and so received three 
scores on each of the CTQ-SF subscales, and three CTQ-SF total scores. To analyse between-
group differences on each of these outcome variables, average scores across the three 
administrations were calculated for each participant. Those average scores were then used in the 
analyses presented in Table 2. 
 
Table 2  
Clinical Characteristics of the Current Sample (N = 38) 
 CTQ-SF outcome variable 
Trauma Control  
t 
 
p 
 
Cohen’s d (n = 16) (n = 22) 
Total Score 53.18 (6.72) 40.88 (1.95) 7.11 < .001*** 2.68 
Emotional Abuse 11.08 (4.11) 7.09 (1.23) 3.77 < .001*** 1.42 
Physical Abuse 8.05 (2.62) 5.61 (0.87) 3.58 < .01** 1.34 
Sexual Abuse 6.72 (2.52) 5.08 (0.25) 2.60 < .01** 1.00 
Emotional Neglect 11.96 (4.30) 7.09 (1.54) 4.33 < .001*** 1.62 
Physical Neglect 7.25 (2.46) 5.68 (0.85) 2.44 < .05* 0.92 
Note. Means are presented with standard deviations in parentheses. CTQ-SF = Childhood 
Trauma Questionnaire – Short Form. All t-tests are 1-tailed, calculated with separate variance 
estimates. 
 
  As the table shows, a series of one-tailed t-tests was performed on the data. The a priori 
prediction here was that the Trauma and Control groups would differ significantly across all the 
outcome variables of the CTQ-SF, and that, more specifically, participants in the Trauma group 
would show significantly higher scores than those in the Control group on all of the outcome 
variables. For all comparisons, the assumption of homogeneity of variances was not upheld, and 
therefore separate estimates of variance were used. As expected given the study’s inclusion 
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criteria, and as shown in the table, there were statistically significant between-groups differences 
in the expected direction on all of the CTQ-SF outcome variables. 
  The effect size is a measure of the size of the difference between two variables (Cohen, 
1988). Results for effect sizes reported in the table show that the between-groups differences on 
all the CTQ-SF outcome variables are quite large (for all comparisons, d > 0.9).   
According to the descriptive severity ratings for the CTQ-SF subscale scores (see Table 
A1 in Appendix A), participants in the Trauma group received, on average, “low to moderate” 
scores on all the subscales except Physical Neglect (PN). For PN, the Trauma group achieved, on 
average, a “none to minimal” rating. The Control group received, on average, “none to minimal” 
ratings on all the subscales, as was expected. Despite both groups being in the same descriptive 
range for PN, the Trauma group still had significantly higher average scores on this subscale. 
These findings therefore confirm the a priori predictions for these data.     
 
Test-Retest Reliability of the CTQ-SF  
 In order to estimate the test-retest reliability of the CTQ-SF, Pearson’s correlations were 
computed across three questionnaire administrations. The interval between administration 1 and 
administration 2 (Interval I) lasted on average 9 weeks (M = 8.636, SD = 9.373), while the 
interval between administration 2 and administration 3 (Interval II) lasted on average 11 weeks 
(M = 10.833, SD = 6.337). The interval between administration 1 and administration 3 (Interval 
III) obviously had the longest average time-span in weeks (M = 18.818, SD = 10.505). 
 Table 3 presents the relevant correlation coefficients. The Trauma and Control group data 
were collapsed to have CTQ-SF outcome variable scores for the entire sample.  Participants who 
had missing data for any of the three administrations were excluded from the analysis, leaving a 
total sample size of N = 29.  
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Table 3  
CTQ-SF Test-Retest Reliability Estimates (N = 29) 
 CTQ-SF outcome variable Interval I Interval II Interval III  
Total Score .80* .84* .76*  
Emotional Abuse .88* .77* .75*  
Physical Abuse .89* .80* .73*  
Sexual Abuse .89* .58* .83*  
Emotional Neglect .87* .87* .87*  
Physical Neglect          .38* .37* .29  
Note. CTQ-SF = Childhood Trauma Questionnaire - Short Form. Data presented are 
Pearson’s correlation coefficients (r). Interval I = time between administration 1 and 
administration 2; Interval II = time between administration 2 administration 3; 
Interval III = time between administration 1 and administration 3. 
*p < .05. 
 
 The results show statistically significantly high positive correlations (varying between r = 
.37 and .89) for most of the CTQ-SF subscales across time. Not taking into account the PN 
correlations, which were the lowest and are discussed in more detail below, correlations for the 
five remaining outcome variables ranged between .73 and .89, with only the Sexual Abuse (SA) 
Interval II correlation falling below this range. These figures can be interpreted as follows: Those 
correlations ranging from .29 to 38, that is, all PN correlations, are regarded as low, and as 
representing a definite but small relationship. The correlation for SA Interval II (r = .58) is 
regarded as moderate in strength and is indicative of a substantial relationship between the 
variables measured. Finally, the remaining correlations, all of which range between .73 and .89, 
are regarded as high, and as representative of a strong relationship between the variables 
measured (Tredoux & Durrheim, 2002). For the most part, then, these statistics are suggestive of 
very good test-retest reliability for the instrument.   
 The original long form of the CTQ (consisting of 70 question items) showed similar test-
retest reliability over a 2- to 6-month interval (Bernstein et al., 1994), a similar time span as 
covered in the current study. Specifically, the results showed an intraclass correlation (ICC; a 
type of correlation that measures the degree of relationship between units that are organized into 
groups) of .88. Subsequent research found similar figures for the CTQ subscales ranging from 
correlations of .79 to .86 over an average of 4 months (Bernstein & Fink, 1998). There are no 
published data on the test-retest reliability of the CTQ-SF. 
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With regard to the PN subscale, it appears that within the current sample responses to 
items on this subscale were not as consistent as those on other subscales. For instance, the only 
correlation that was not statistically significant was that for PN Interval III. Furthermore, as the 
Table shows, even at shorter intervals the PN scores produced much lower test-retest reliability 
estimates than did the other outcome variables. 
 Another out of the ordinary finding was the comparatively low test-retest reliability 
estimate of the Sexual Abuse (SA) subscale for Interval II (r = .58, compared to .89 and .83 for 
Interval I and Interval III, respectively). Because this was not the interval with the longest time-
span between sessions, the length of time between administrations cannot account for this pattern 
of findings on the SA subscale. A more viable explanation may be related to the method of 
questionnaire delivery.    
  Method of delivery. In the first testing session of the current study, the CTQ-SF was 
administered using an online questionnaire. Subsequent administrations involved traditional 
paper-and-pencil methods. If there were differences in the quality of data retrieved from either of 
these methods, it should be revealed in the differences in correlation between the scores obtained 
across the different administrations. Specifically, if the quality of data is different for the online 
questionnaire (administration 1) compared to data retrieved via traditional methods 
(administration 2), then the Interval I correlations should be significantly different from the 
Interval II correlations, given that the same method (paper-and-pencil) was used for 
administrations 2 and 3. In addition, there should be no difference between the Interval I and 
Interval III correlations, because both correlations reflect associations between scores collected 
using different methods of delivery.  
Dependent samples t-tests showed there was a statistically significant difference between 
correlations at Interval I (M = 0.783, SD = 0.202) compared to those at Interval III (M = 0.703, 
SD = 0.210), t (5) = 3.379, p = 0.0197. There were no other statistically significant differences 
for any of the other interval comparisons, however. This pattern of data suggests that method of 
delivery did not influence the degree of correlation between testing sessions, but rather that time-
span between sessions may have had an influence on the overall results (although, curiously, not 
on the SA subscale taken alone, as noted above).   
 In summary, the results presented thus far have shown that the Trauma and Control 
groups were well matched on major demographic characteristics, and that participants in the two 
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groups were had significantly different trauma histories, as measured by the CTQ-SF. Further 
analyses of the CTQ-SF data showed excellent test-retest reliability for at least four of the five 
subscales, and on the instrument’s total score, over the three administration occasions. 
 
Testing Hypothesis 1: Between-group differences in BIS/BAS sensitivity  
The first hypothesis of the current study was that adults with a history of childhood 
trauma would have heightened BIS sensitivity when compared to adults without such a history. 
That is, I predicted that participants in the Trauma group would score significantly higher on the 
BIS scale of Carver and White’s (1994) BIS/BAS instrument than those in the Control group. 
Because BAS sensitivity is unrelated to BIS activation, and BAS is not implicated in high 
anxiety groups, such as individuals who have experienced early adversity, no significant 
between-group differences were predicted on the BAS scale. That is t  say, the set of a priori 
predictions (and non-predictions) rested on the fact that Trauma participants would show 
evidence of an overactive BIS because of their history of exposure to traumatic events; the 
Control participants, with no such history, would show no such evidence. 
Four independent samples t-tests were conducted to analyse the BIS/BAS data. Table 4 
presents the results from those analyses. 
 
Table 4  
BIS/BAS Data: Between-groups differences 
 Trauma Control  
Outcome variable (n = 14) (n = 22) t p Cohen’s d 
BAS      
 Drive 8.929 (1.890) 8.500 (1.310) 0.796 .216 .28 
 Fun Seeking 7.929 (2.018) 7.773 (1.428) 0.273 .393 .09 
 Reward Responsive 7.143 (1.916) 7.545 (1.563) -0.683 .250 -.24 
      
BIS 14.214 (2.723) 14.591 (2.826) -0.391 .349 -.14 
Note. Means are presented with standard deviations in parentheses. BIS = Behavioural Inhibition 
Sensitivity; BAS = Behavioural Approach Sensitivity. All t-tests were 1-tailed and calculated 
using pooled variance estimates. 
 
 The table shows that the means and standard deviations for both the BIS and BAS scales 
were similar across the two groups. Results from the t-tests confirmed that, contrary to the a 
priori predictions, there were no statistically significantly between-groups differences on the BIS 
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scale. There were also no such differences on the BAS subscales. Furthermore, effect size 
estimates indicate relatively small variation in the the degree of between-groups differences on 
the BIS/BAS scales. These results suggest that participants in the two groups show similar 
characteristics with regard to their approach and inhibition sensitivities. 
 
Testing Hypotheses 2 and 3: Processing bias for threat-related stimuli in the Trauma group 
and buprenorphine-mediated decrease in processing bias in the Trauma group 
The second hypothesis of the current study was that participants in the Trauma group 
would show an attentional bias for threat-related stimuli (i.e., fearful faces in the Object 
Relocation Task) and avoidance of approach-related stimuli (i.e., angry and happy faces), 
perhaps because of their relatively overactive BIS. The non-confirmatory findings from analyses 
testing Hypothesis 1 made this prediction more tentative; nonetheless, it remained possible that 
attentional bias in the Trauma group might still have been evident despite the lack of between-
group differences on the BIS/BAS scales. 
The third hypothesis of the current study was that any increased attentional bias for 
threat-related stimuli in Trauma participants would be decreased by administration of the mu-
opioid buprenorphine, and that this decrease w uld not be observed in Control participants. 
Clearly, then, Hypotheses 2 and 3 are closely related to one another, and so an analysis testing 
both of them is presented in this section. 
The relevant analysis here involved data from the Object Relocation Task. Specifically, 
the prediction was that participants in the Trauma group would show attentional bias towards 
threat-related stimuli (i.e., fearful faces) and avoidance of approach-related stimuli (i.e., angry 
and happy faces) in the task. This means Trauma group participants should, compared to 
participants in the Control group, perform with less error in relocating fearful faces and more 
error in relocating angry and happy faces. Furthermore, the prediction was that the effect of 
buprenorphine activity would be to decrease the attentional bias for threat-related stimuli in 
Trauma participants, but would have no such impact in Control participants. The outcome 
variable here, then, was the deviation in millimetres between the relocated position for each face 
and its original position. Indices for attentional bias were derived by subtracting performance on 
emotional (angry/fearful/happy) faces from performance on neutral faces. 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
47 
 
A 2 x 6 repeated-measures factorial ANOVA, with trauma profile as the between-
subjects factor, allowed testing of the hypotheses. For the within-subjects factor, medication 
condition (placebo/medication) was collapsed with the emotional faces conditions 
(anger/fear/happy) giving a general performance for the Object Relocation Task across the 
medication and placebo conditions. Thus, each participant received six scores, three scores under 
the placebo condition (one for each of the types of emotional faces), and three scores under the 
medication condition (again, one for each of the types of emotional faces). 
Table 5 presents the descriptive statistics for the data analysed using the repeated-
measures factorial ANOVA. 
Placebo. Table 5 shows that, with regard to fearful faces in the placebo condition, 
participants in the Trauma group had higher mean deviation scores (and therefore performed 
with greater error) than participants in the Control group. This piece of data is contrary to the 
predictions set out in Hypothesis 2. Fearful faces represent threatening stimuli, and in individuals 
with high levels of anxiety, these faces should preoccupy their attention and thereby lead to more 
error-free performance than healthy controls. What the descriptive statistics in Table 5 suggest, 
instead, is an avoidance of threatening stimuli by Trauma group participants. (Avoidance of the 
threat-provoking stimuli would cause less attention to be directed at the stimuli and therefore 
worsen recall of the original position those faces resulting in the type of error observed in the 
fearful faces condition outlined here.) The results also show that, with regard to angry faces in 
both the placebo and medication conditions, participants in the Trauma group achieved lower 
error scores than participants in the Control group, suggesting a bias for angry faces. Happy 
faces appear to have produced similar amounts of error in Trauma and Control groups. These 
findings are contrary to the predictions set out in Hypothesis 2. 
Curiously, this is the type of performance that high-anxiety participants achieve for tasks 
that are subject to conscious control mechanisms, such as the emotional Stroop task (e.g., see, 
van Honk et al., 1998). 
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Table 5  
Performance on the Object Relocation Task (N = 38) 
 Trauma Control
Condition/Emotion (n = 16) (n = 22) 
Placebo   
 Anger 21.203 (7.804) 23.623 (9.522) 
 Fear 23.238 (11.470) 20.895 (10.798) 
 Happy 24.884 (13.084) 24.288 (12.262) 
Medication   
 Anger 22.576 (7.696) 23.684 (10.273) 
 Fear 21.456 (8.401) 21.766 (9.640) 
 Happy 23.394 (9.462) 24.355 (10.661) 
Note. Statistics are for deviation in millimetres of the position of the relocated emotional face 
from the position of the relocated neutral face. Means are presented with standard deviations in 
parentheses. 
 
 Medication. Table 5 shows that, with regard to fearful faces and in contrast to the pattern 
of data for the placebo condition, error scores were quite similar across groups. Further with 
regard to fearful faces, the Table also shows that Trauma participants had larger deviation scores 
in the placebo condition than in the medication condition. Finally, and also with regard to fearful 
faces, Table 5 shows that Control participants had larger deviation scores in the medication than 
in the placebo condition. In fact, it appeared that the error across the fearful faces trials increased 
for the Control group. 
These observations stand in contrast to the predictions made by Hypothesis 3. However, 
they would be expected if performance on the Object Relocation Task was subject to conscious 
control mechanisms. Notably, the purpose of administration of buprenorphine in the present 
study was to reduce the processing bias observed in trauma samples so that performance is more 
similar to that of healthy controls in the same task. The descriptive statistics for the relocation of 
fearful faces in the medication condition for the Trauma and Control groups do appear more 
similar than those in the placebo condition.   
Inferential statistics for Object Relocation Task data. Assumptions of normality of data 
distribution and homogeneity of variances were upheld. The omnibus F-test showed non-
significant interaction effects for trauma profile and object relocation across medication 
conditions, F(5, 180) = 0.255, p = .937. The main effects for trauma profile and object relocation 
across medication conditions were also not statistically significant, F(1, 36) = 0.036, p = .850, 
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and F(5, 180) = 0.490, p = .784, respectively. It therefore appears that although the trends in 
observed in the descriptive statistics contradicted the predictions made by Hypotheses 2 and 3, 
those trends were not strong enough to deliver statistical significance. 
Analyses of the data provided no statistical support for the hypotheses set out in the 
current study. Implications and possible explanations of these results are discussed, and 
recommendations for future research are made, in the following section. 
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DISCUSSION 
The current study compared personality characteristics and cognitive functioning 
(specifically, attentional bias) in a sample of adults who had experienced childhood trauma (the 
Trauma group) and a matched healthy control group. The study also examined the possible 
effects of the mu-opioid agonist buprenorphine on attentional bias in the Trauma group. 
The first objective explored in the current research was to examine the test-retest 
reliability of the CTQ-SF, an instrument widely regarded as well-suited for obtaining self-reports 
from adults about adverse events during childhood (Thombs et al., 2007), but for which no test-
retest reliability data is currently available. The CTQ-SF was administered to the sample on three 
separate occasions. This allowed for reliability testing across multiple sessions, over time. The 
method of questionnaire delivery, and its possible effect on test performance, was analysed.  
The next set of objectives explored in the current research involved three specific 
hypotheses: Hypothesis 1 stated that, with regard to BIS/BAS sensitivity, I predicted that adults 
with a history of childhood trauma would have heightened activation of the behavioural 
inhibition system. This increased BIS activity would, I predicted, be reflected in relatively higher 
scores on the BIS dimension of Carver and White’s (1994) BIS/BAS scale. No significant 
differences were predicted for BAS sensitivity. Hypothesis 2 stated that, with regard to 
performance on the Object Relocation Task, adults with a history of childhood trauma would 
demonstrate an information-processing bias for threat-related stimuli and avoidance of approach-
related stimuli, reflected in significantly less error for relocating fearful faces to their original 
locations and more error for relocating angry and happy faces to their original locations, 
compared to healthy matched controls. Hypothesis 3 stated that buprenorphine would alleviate 
the attentional bias for fearful faces described above.  
Hence, the overall aim of the research was to explore the developmental outcome of early 
adversity on adult information processing, while examining the possibility of intervention for 
trauma-related information-processing bias. Unfortunately, however, the current data did not 
confirm the a priori hypotheses with regard to personality, information-processing bias, and 
effects of buprenorphine. In this section, I discuss these negative findings in light of the Trauma 
group’s performance on the CTQ-SF and the effects of severity of traumatic experiences on 
personality traits, information-processing bias, and mu-opioid receptor activity. 
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CTQ-SF Analyses 
Preliminary statistical analyses confirmed the a priori predictions that the Trauma and 
Control groups would differ significantly on all the outcome variables of the CTQ-SF, with 
Trauma group participants scoring significantly higher than Control group participants in each 
case. The descriptive severity ratings for the CTQ-SF subscale scores (see Table A1 in Appendix 
A) indicated that participants in the Trauma group received, on average, “low to moderate” 
scores on all the subscales except Physical Neglect (PN). For PN, the Trauma group achieved, on 
average, a “none to minimal” rating. The Control group received, on average, “none to minimal” 
ratings on all the subscales, as was expected given our recruiting strategies. Furthermore, despite 
the scores of both groups being in the same descriptive range for PN, the Trauma group still had 
significantly higher average scores on this subscale.  
Bernstein et al. (2003) constructed and validated the 28-item CTQ-SF from items that 
were part of the original CTQ. However, no current data are available for the test-retest 
reliability of the CTQ-SF, and that is why I set out to provide such data. My analyses suggested 
very good test-retest reliability for four of the five subscales. Specifically, the test-retest 
reliability of the CTQ-SF in the current study proved to be very good: There were statistically 
significantly high positive correlations (varying between r = .37 and .89) for most of the CTQ-SF 
subscales across time. Not taking into account PN correlations (for reasons outlined in the 
Results section, and discussed further below), the correlations of participant scores on the five 
remaining subscales across repeated administrations indicated substantial and strong agreement 
between responses. 
The original long form of the CTQ (consisting of 70 items) showed similar test-retest 
reliability over a 2- to 6-month interval (Bernstein et al., 1994). Bernstein and colleagues 
administered the 70-item CTQ to 286 drug- or alcohol-dependent patients, and then after 2 to 6 
months administered it for a second time to 40 of these individuals. The results showed an ICC 
of .88. Subsequent research found similar figures for the CTQ subscales, ranging from 
correlations of .79 to .86 over an average of 4 months (Bernstein & Fink, 1998).  
With regard to the PN subscale, it is notable that scores generated low correlations over 
the two time intervals, and that scores at the initial administration failed to predict scores at the 
two subsequent administrations. This pattern of data may have arisen because of problems with 
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the internal validity of the neglect constructs (Gerdner & Allgulander, 2009). In a study 
exploring the factor structure, internal consistency, and content validity of a Swedish translation 
of a 53-item CTQ, the authors found four of the five subscales homogenous and internally 
consistent (Lundgren, Gerdner, & Lundquist, 2002). The PN subscale was the only one observed 
to lack homogeneity in its factor structure, and the authors criticized the content validity of some 
of the items on that subscale. In a similar study examining the factor structure, internal 
consistency, inter-correlations of subscales, and sensitivity to social desirability of the same 
Swedish version of the CTQ-SF, findings further suggested a lack of homogeneity for the PN 
subscale (Gerdner & Allgulander, 2009). The authors of both studies pointed out that the neglect 
constructs are theoretically vague and that the PN items should, rather than referring to “physical 
neglect”, instead be interpreted as referring to a “lack of care” and/or a “lack of supervision”. 
Overall, their recommendations were that that the PN scale should be revised. 
Given the validity problems for the PN items pointed to by these previous studies, it is 
possible that the participants in the current sample interpreted those items differently at the 
different administrations, thus providing responses at the final administration that were not in 
agreement with their initial efforts.  
Another out of the ordinary, albeit more curious, finding was the comparatively low test-
retest reliability estimate of the SA subscale for Interval II (r = .58, compared to .89 and .83 for 
Interval I and Interval III, respectively). Neither length of time between administrations, nor 
method of questionnaire delivery was found to account for the result. It would be interesting to 
see how this variable performs in subsequent psychometric research.   
I undertook additional analyses of the CTQ-SF data to examine whether the method of 
questionnaire delivery made a difference to participants’ CTQ-SF responses. The initial 
administration was undertaken online using a web-based questionnaire, whereas subsequent 
administrations were undertaken using traditional paper-and-pencil questionnaires. An important 
mediating factor for the validity of personal disclosure is anonymity and confidentiality. Because 
Web-based questionnaires are responded to in private, without an experimenter present, it is 
possible that such delivery methods may reduce response bias emerging from social desirability 
effects (Huang, 2006). However, in presenting data contrary to that argument, Gosling, Vazire, 
and Srivastava (2004) found that, when compared with data derived from traditional methods 
published in the Journal of Personality and Social Psychology (JPSP) within the year 2002, data 
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retrieved using an online questionnaire appeared to be consistent with results from those 
traditional methods. 
The results reported in the present study support the finding that Web-based 
questionnaires may produce data consistent with those produced by traditional survey methods. 
More specifically, the results showed that there was a statistically significant difference between 
correlations at Interval I compared to those at Interval III, while no other statistically significant 
differences for any of the other interval comparisons were observed. The data therefore suggest 
that method of questionnaire delivery did not influence the degree of correlation between testing 
sessions, but rather that time-span between sessions may have had an influence on the overall 
results.  
In summary, the findings generated from CTQ-SF data analyses showed that the 
instrument differentiated reliably between adults with a history of childhood maltreatment and 
healthy matched controls across four of its five subscales. In addition, findings suggested that the 
method of questionnaire delivery did not affect the degree of agreement across administration 
intervals of the CTQ-SF subscales, but that degree of agreement was, instead, affected by 
differences in time-span between administration intervals.  
 
Hypothesis 1: Between-group differences in BIS/BAS sensitivity  
The analyses of BIS/BAS sensitivity in the current sample revealed that, contrary to the a 
priori prediction, there were no statistically significantly between-group differences in terms of 
BIS scale scores. There were also no such differences in terms of BAS subscale scores. These 
results suggest that participants in the two groups reported similar characteristics with regard to 
their approach and inhibition sensitivities. It is possible that these results are attributable to 
participants in the Trauma group having “low to moderate” severity ratings on most of the CTQ-
SF subscales, suggesting only mild traumatic histories/experiences, and therefore reducing the 
possibility of subsequent developmental pathology in adult life. 
There are consistent reports in the literature linking severity of early adversity, 
characterised by repetitive, persistent, or intense exposure to the traumatic event(s), to the 
development of maladaptive personality structures, cognitive biases, mood states, and 
behavioural tendencies in adulthood (see, e.g., Sansone & Sansone, 2007; Teicher et al., 2002, 
2003). One possible mechanism underlying these maladaptive developmental paths involves a 
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process whereby the stress response becomes sensitized by persistent re-experiencing of the 
traumatic event(s). Persistent stress sensitization then results in increased stress responsiveness to 
threatening stimuli, and a general and chronic hyperarousal of the stress response system 
(Teicher et al., 2002, 2003). This heightened responsiveness and state of arousal is considered a 
stable trait-like feature of the personality of the victim (Perry, 1995), and it is this trait that is 
considered the source of anxiety and the link to an increased BIS in individuals with traumatic 
histories (McNaughton & Corr, 2004). It is therefore argued here that the severity of childhood 
traumatic experiences in the current Trauma group participants did not reach the level of severity 
sufficient to alter their neurodevelopment and to thereby increase BIS sensitivity.  
Additionally, the current study’s Trauma group was a non-clinical sample of university 
students. Previous research that examined the BIS/BAS scales in a similar non-clinical sample of 
students also found no significant differences on the BIS/BAS scales between those with 
elevated basal levels of the stress hormone cortisol (a measure of the HPA-axis stress response) 
and those with lower levels (Putman, van Honk, Kessels, Mulder, & Koppeschaar, 2004).      
In contrast, the findings presented by Rosenman and Rodgers (2006) suggest that higher 
levels of adverse childhood experiences increase the risk of higher BIS sensitivity significantly, 
whereas there is no significant relationship between childhood adversity and BAS sensitivity. In 
that study, individuals in a large randomly-selected community sample (N = 7485) were 
interviewed about their history, social circumstances, personality and cognitive function, recent 
psychological symptoms, and substance use. The participants were also asked 17 questions, each 
enquiring about adverse childhood experiences. The participants’ responses to these questions 
were then analysed against their responses on the Carver and White (1994) BIS/BAS scales, and 
their risk for BIS/BAS sensitivity computed as an odds ratio. The findings showed a low but 
significant risk (odds ratio = 1.7) for behaviour inhibition. Importantly, the authors measured the 
odds ratio between early adversity and BIS in subjects with the highest levels of childhood 
adversity. Only subjects with 5 or more adverse experiences were included in the “high 
adversity” category, while the rest made up the “low adversity” category. In contrast, the present 
study’s inclusion criteria for individuals in the Trauma group required that participants achieve a 
moderate to severe score on at least one CTQ-SF subscale. Additionally, the highest severity 
rating the Trauma group received, on average, was in the “low to moderate” range. Hence, in 
comparing the inclusion criteria for the present study with those of Rosenman and Rodgers 
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(2006), it appears possible that the earlier study included a trauma group (i.e., the high adversity 
group) with a more severe history of adverse experiences compared to the Trauma group in the 
current study. 
Furthermore with regard to accounting for the pattern of the current non-significant 
results, Putman et al. (2004a) grouped their participants according to those with elevated and 
those with low basal levels of cortisol. Hypercortisolism has been associated with various 
anxiety and depressive disorders (Teicher et al., 2002) and elevated inhibited, avoidant 
motivation (Putman et al., 2007); nonetheless, Putman et al. (2004a) failed to find a significant 
correlation between basal cortisol levels and BIS/BAS scale scores. Furthermore, in that study, 
the “high cortisol” group showed only moderately elevated levels (with a mean cortisol level of 
12.8 nmol/l) and only moderately elevated trait anxiety. The authors stated that these levels were 
within the range of healthy individuals. These findings, together with those reported in the 
present study, suggest that Carver and White’s (1994) BIS/BAS scales, in particular the BIS 
scale, may not be sensitive to mild-to-moderate levels of anxiety and childhood adversity in non-
clinical samples of individuals. 
Interestingly, the trends observed in the current BIS/BAS raw data suggest increased 
BAS sensitivity for the Trauma group (specifically on the “Drive” and “Fun Seeking” subscales) 
compared to the Control group. In contrast, the Control group scored higher on the BAS 
“Reward Responsiveness” subscale and on the BIS scales. The effect sizes for all these 
comparisons were within the small range, however, suggesting the real-world relevance of these 
differences are rather minimal. It would be of interest to see whether future research efforts can 
clarify further the relationship between CTQ-SF scores and BIS/BAS sensitivity.     
In summary, the results of the present study did not provide support for the hypothesis 
that individuals in the Trauma group would have significantly increased BIS sensitivity relative 
to those in the Control group. One possibility is that participants in the current Trauma group did 
not have sufficiently high severity ratings on the subscales of the CTQ-SF to develop heightened 
BIS activation (Trauma group scores for CTQ-SF subscales: EA: M = 11.08, SD = 4.11 (severe 
to extreme = 16 and above); PA: M = 8.05, SD = 2.62 (severe to extreme = 13 and above); SA: 
M = 6.72, SD = 2.52 (severe to extreme = 13 and above); EN: M = 11.96, SD = 4.30 (severe to 
extreme = 18 and above); PN: M = 7.25, SD = 2.46 (severe to extreme = 13 and above)). 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
56 
 
Hypothesis 2:  Processing bias for threat-related stimuli in the Trauma group 
The current data did not support the a priori hypothesis that Trauma group participants 
would show an attentional bias for threat-related stimuli (i.e., fearful faces in the Object 
Relocation Task) and avoidance of approach-related stimuli (i.e., angry and happy faces on the 
Object Relocation Task). 
A model for the neurodevelopmental pathway of child trauma victims, outlined by 
researchers such as Teicher et al. (2003, 2002) and Perry et al. (1995), would place adults with a 
history of early adversity at risk for various behavioural, emotional, and cognitive disorders. 
However, in the current study no cognitive distortions, in the form of an information-processing 
bias related to emotional faces, were observed for Trauma group participants. Instead, there were 
no between-group differences in performance on the Object Relocation Task: participants in the 
Trauma and Control groups performed equally under all emotional face conditions. 
One might argue that this pattern of non-significant between-group differences was to be 
expected in light of the fact that the groups did not differ in terms of their BIS and BAS 
sensitivity. More specifically, if participants in the two groups showed similar levels of BIS and 
BAS sensitivity, then one would expect that they would process both avoidance-related stimuli 
(e.g., fearful faces on the Object Relocation Task) and approach-related stimuli (e.g., angry and 
happy faces on the Object Relocation Task) in a similar manner—and this similar processing is 
exactly what the results showed. 
These results for the Object Relocation Task can therefore be interpreted in light of the 
mild-to-moderate level of trauma severity the Trauma group reported experiencing during 
childhood. Otherwise stated, the severity of their adverse childhood experiences was not 
sufficient to produce disruptions in information-processing for emotional stimuli, resulting in 
performance similar to that of the Control group on the Object Relocation Task.         
 
Hypothesis 3: Buprenorphine mediated decrease in processing bias for the Trauma group 
Analyses of the effects of the mu-opioid buprenorphine on information-processing bias in 
adults with a history of childhood trauma provided no support for the a priori prediction that 
attentional bias for threat-related stimuli (i.e., fearful face on the Object Relocation Task) in 
Trauma participants would be decreased by administration of the drug, and that this decrease 
would not be observed in Control participants. 
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The a priori prediction was made in the knowledge, based on previous literature, that 
endogenous opioids such as buprenorphine reduce expression of the fear response in individuals 
with traumatic histories by dampening the autonomic fear response and blunting the affective 
component of stress (see, e.g., Drolet et al., 2001; Panksepp, 2003). As noted above, however, 
Trauma-group participants in the current study did not have histories of severe childhood 
adversity; they also did not exhibit any personality-related differences compared to control 
participants, or respond differently to emotional stimuli. It was therefore more difficult to 
examine any effects buprenorphine may have had on the performance of those participants, given 
that the drug works by offsetting a hyper-sensitive stress response and the current Trauma 
participants may not have had such a disordered physiological status. However, despite the non-
significant inferential statistical findings, the descriptive trends in the data are to be noted.  
The descriptive data show the Trauma group committed less error in relocating fearful 
faces in the medication condition, compared to that groups’ performance in the placebo 
condition. These results were contrary to the predictions made in Hypothesis 3, namely, that any 
increased attentional bias for threat-related stimuli (less error in relocating fearful faces when 
compared to controls) in Trauma participants would be decreased (more error in relocating 
fearful faces relative to the Trauma groups’ performance in placebo condition) by administration 
of the mu-opioid agonist buprenorphine.  
Specifically, the findings showing less error in relocating fearful faces in the medication 
condition, suggest the Trauma participants exhibited increased bias for threat-related stimuli 
during the medication condition, reflected by the larger error scores, relative to their performance 
in the placebo condition. However, this piece of data may also be interpreted as the Trauma 
group demonstrating less avoidance of fearful faces in the medication condition, compared to 
their performance in the placebo condition. Avoidance of threat related stimuli in individuals 
with elevated levels of anxiety is associated with conscious control mechanisms in non-clinical 
samples (Bar-Haim et al., 2007; van Honk, et al., 1998). Thus, the more anxiety an individual 
feels the more that individual consciously avoids anxiety-provoking stimuli. The descriptive 
findings for buprenorphine effects on attentional bias may therefore be interpreted to suggest that 
the mu-opioid agonist did exert anxiolytic effects in the Trauma group, resulting in the group 
requiring less conscious avoidance of the threat-related stimuli. This conclusion is however 
tentative, and requires further investigation.   
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Limitations and Directions for Future Research 
A primary limitation of the present study is the Trauma groups’ relatively moderate 
severity of traumatic experiences in childhood. The moderate nature of this group’s average 
severity rating on the CTQ-SF suggests that they may not have been subject to the range of 
neurodevelopmental changes that are needed to produce increased sensitivity to threat-related 
stimuli. Future studies should examine whether the increased severity of traumatic experiences in 
childhood, as measured by the CTQ-SF, is related to maladaptive BIS/BAS personality traits and 
biases in information processing.    
A second potential limitation of the present study was the rather small sample size. 
Studies that have examined elevated anxiety, BIS/BAS traits, and information-processing bias 
have, however, used similarly-sized samples (see, e.g., Putman et al., 2004; van Honk et al., 
2007, 2003, 1998; van Honk & Shutter, 2006). The descriptive results reported in the present 
study for the Object Relocation Task contradict the trends found by other researchers who 
believe this task surpasses the need for supraliminal and subliminal presentation of stimulus 
items (van Honk et al., 2003). Furthermore, the descriptive results for the BIS/BAS scales also 
showed contradictory trends from what was expected from the Trauma participants. A larger 
sample size would help clarify whether the performances on the Object Relocation Task 
observed in the present study were due to chance or to actual between-groups differences. 
A third potential limitation of the current study was the fact that the measure of behavior 
inhibition and activation was a self-report measure. We can therefore only make indirect 
inferences about the actual level of activity in behavioural inhibition and activation systems. 
Brenner, Beauchaine, and Sylvers (2005) compared Carver and White’s (1994) BIS/BAS scale to 
physiological markers of BIS and BAS reactivity during reward and extinction. The authors 
found low correlations between the BIS/BAS scales and physiological measures. The only 
sizeable correlation they observed was between scores on the BAS Reward Responsiveness 
subscale and respiratory sinus arrhythmia (r = .37, p < .01). In contrast, scores on the BIS/BAS 
scales correlated more strongly with scores on the Positive and Negative Affect Schedule 
(PANAS; Watson et al., 1988). These findings suggest that the BIS/BAS scale is more strongly 
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associated with self-reported measures of affect than physiological markers of reward and 
extinction. Future research efforts should therefore use multiple measures of the BIS and BAS 
constructs in order to get a clearer picture of the state of activity along those dimensions within 
their participants.  
A fourth potential limitation of the current study is that the dosage of buprenorphine 
administered to the sample may have been too small to mediate attenuation of an information-
processing bias. Research suggests that placebo responses, in particular placebo analgesia, may 
share a similar neural network to the endogenous opioid system (Petrovic, 2005). The placebo in 
the present research may therefore have caused similar activation levels as buprenorphine, given 
the current dosage (0.2mg). Future research would therefore need to increase the dosage in naïve 
individuals; however it would have to do so ethically, that is, without increasing negative side-
effects. The answer may be to use a mu-opioid receptor blockade as the control condition, not 
placebo. mu-Opioid receptor blockers are drugs that bind to but do not activate the mu-opioid 
receptor (e.g., see, Krishnan-Sarin, Wand, Li, Potoghese, & Froehlich, 1998), thereby controlling 
for possible placebo effects on those receptors.  
Finally, the overarching research study, of which this forms part, constitutes a first step in 
investigating the use of new generation opioids in certain psychiatric disorders. Research using 
such opioids in opioid naïve individuals is almost non-existent – hence the decision to start with 
a sample of essentially healthy controls (i.e., no psychiatric morbidity) who were only 
differentiated on self-reported level of exposure to early social trauma. This may help explain 
why the Trauma group responded with relatively ‘mild’ severity ratings, and the resultant null 
findings. As the program progresses, participants with more severe clinical pathology will be 
included – but the current sample was decided on ethical principles.  
 
Conclusion and Implications 
The current study compared personality characteristics and cognitive functioning 
(specifically, attentional bias) in a sample of adults who had experienced childhood trauma (the 
Trauma group) and a matched healthy control group. The study also examined the possible 
effects of the mu-opioid agonist buprenorphine on attentional bias in the Trauma group. 
 The data presented in this thesis showed that, as a measure of childhood trauma, the 
CTQ-SF generated good test-retest reliability on four of its five subscales over variable lengths 
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of time, even given different methods of survey delivery across administrations. In addition, I 
found that participants with a history of childhood trauma did not differ from matched controls 
with regard to the current study’s indices of behavioral approach and inhibition, and with regard 
to attentional bias. Furthermore, buprenorphine demonstrated no observable alleviation of 
attentional bias in individuals with histories of early adversity. One possible explanation for the 
lack of between-group differences may be related to the moderate severity of adverse 
experiences reported by the Trauma group. 
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APPENDIX A 
Guidelines for Interpretation of CTQ-SF Scores 
Table A1 
 Severity Rating 
CTQ-SF Subscale 
None or 
minimal 
Low to 
moderate 
Moderate to 
severe 
Severe to 
extreme 
Emotional Abuse 5-8 9-12 13-15 16 and above 
Physical Abuse 5-7 8-9 10-12 13 and above 
Sexual Abuse 5 6-7 8-12 13 and above 
Emotional Neglect 5-9 10-14 15-17 18 and above 
Physical Neglect 5-7 8-9 10-12 13 and above 
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APPENDIX B 
The Childhood Trauma Questionnaire-Short Form 
 
 
Patient  
Name 
    Week Visit  Date DD MMM YYYY 
Childhood Trauma Questionnaire – Short Form (CTQ-SF) 
Copyright 1996 David P. Bernstein, Ph.D., Laura Fink, Ph.D. 
Instructions: These questions ask about some of your experiences growing up as a 
child and a teenager. For each question, circle the number that best describes how 
you feel. Although some of these questions are of a personal nature, please try to 
answer as honestly as you can. Your answers will be kept confidential. 
 
 
 
 
 
When I was growing up, … 
N
ever True 
R
arely True 
Som
etim
es True 
O
ften True 
Very O
ften True 
1. I didn’t have enough to eat. 1 2 3 4 5 
2. I knew there was someone to take care of me and protect me 1 2 3 4 5 
3. People in my family called me things like “stupid”, ”lazy”, or “ugly”. 1 2 3 4 5 
4. My parents were too drunk or high to take care of me. 1 2 3 4 5 
5. There was someone in my family who helped me feel important 
or special. 
1 2 3 4 5 
6. I had to wear dirty clothes. 1 2 3 4 5 
7. I felt loved. 1 2 3 4 5 
8. I thought that my parents wished I had never been born. 1 2 3 4 5 
9. I got hit so hard by someone in my family that I had to see a 
doctor or go to the hospital. 
1 2 3 4 5 
10. There was nothing I wanted to change about my family. 1 2 3 4 5 
11. People in my family hit me so hard that it left bruises or marks. 1 2 3 4 5 
12. I was punished with a belt, a board, a cord, or some hard object. 1 2 3 4 5 
13. People in my family looked out for each other. 1 2 3 4 5 
14. People in my family said hurtful or insulting things to me. 1 2 3 4 5 
15. I believe that I was physically abused. 1 2 3 4 5 
16. I had the perfect childhood. 1 2 3 4 5 
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17. I got hit or beaten so badly that it was noticed by someone like a 
teacher, neighbour, or doctor. 
1 2 3 4 5 
18. I felt that someone in my family hated me. 1 2 3 4 5 
19. People in my family felt close to each other. 1 2 3 4 5 
20. Someone tried to touch me in a sexual way, or tried to make me 
touch them. 
1 2 3 4 5 
21. Someone threatened to hurt me or tell lies about me unless I did 
something sexual with them. 
1 2 3 4 5 
22. I had the best family in the world. 1 2 3 4 5 
23. Someone tried to make me do sexual things or make me watch 
sexual things. 
1 2 3 4 5 
24. Someone molested me. 1 2 3 4 5 
25. I believe that I was emotionally abused. 1 2 3 4 5 
26. There was someone to take me to the doctor if I needed it. 1 2 3 4 5 
27. I believe that I was sexually abused 1 2 3 4 5 
28. My family was a source of strength and support. 1 2 3 4 5 
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APPENDIX C 
The BIS/BAS Scale 
 
Each item of this questionnaire is a statement that a person may either agree with or disagree with.  For 
each item, indicate how much you agree or disagree with what the item says.  Please respond to all the 
items; do not leave any blank.  Choose only one response to each statement.  Please be as accurate and 
honest as you can be.  Respond to each item as if it were the only item.  That is, don't worry about being 
"consistent" in your responses. 
 
 
 
1) A person's family is the most important thing in life.  
 
              1   2                     3                        4 
very true for me          somewhat true for me    somewhat false for me         very false for me 
 
 
 
2)  Even if something bad is about to happen to me, I rarely experience fear or nervousness.  
 
              1   2                     3                        4 
very true for me          somewhat true for me    somewhat false for me         very false for me 
 
 
 
3)  I go out of my way to get things I want.  
 
              1   2                     3                        4 
very true for me          somewhat true for me    somewhat false for me         very false for me 
 
 
 
4)  When I'm doing well at something I love to keep at it.  
 
     1   2                     3                        4 
very true for me          somewhat true for me    somewhat false for me         very false for me 
 
 
 
5) I'm always willing to try something new if I think it will be fun.  
 
    1   2                     3                        4 
very true for me          somewhat true for me    somewhat false for me         very false for me 
 
 
 
  6) How I dress is important to me.  
 
    1   2                     3                        4 
very true for me          somewhat true for me    somewhat false for me         very false for me 
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7)  When I get something I want, I feel excited and energized.  
 
    1   2                     3                        4 
very true for me          somewhat true for me    somewhat false for me         very false for me 
 
 
 
8)  Criticism or scolding hurts me quite a bit.  
 
    1   2                     3                        4 
very true for me          somewhat true for me    somewhat false for me         very false for me 
 
 
 
9)  When I want something I usually go all-out to get it.  
 
    1   2                     3                        4 
very true for me          somewhat true for me    somewhat false for me         very false for me 
 
 
 
10)  I will often do things for no other reason than that they might be fun.  
 
    1   2                     3                        4 
very true for me          somewhat true for me    somewhat false for me         very false for me 
 
 
 
11) It's hard for me to find the time to do things such as get a haircut.  
 
    1   2                     3                        4 
very true for me          somewhat true for me    somewhat false for me         very false for me 
 
 
 
12) If I see a chance to get something I want I move on it right away. 
 
    1   2                     3                        4 
very true for me          somewhat true for me    somewhat false for me         very false for me 
  
 
 
 13) I feel pretty worried or upset when I think or know somebody is angry at me.  
 
    1   2                     3                        4 
very true for me          somewhat true for me    somewhat false for me         very false for me 
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14) When I see an opportunity for something I like I get excited right away.  
 
    1   2                     3                        4 
very true for me          somewhat true for me    somewhat false for me         very false for me 
 
 
15) I often act on the spur of the moment.  
 
    1   2                     3                        4 
very true for me          somewhat true for me    somewhat false for me         very false for me 
 
 
 
16) If I think something unpleasant is going to happen I usually get pretty "worked up."  
 
    1   2                     3                        4 
very true for me          somewhat true for me    somewhat false for me         very false for me 
 
 
 
17) I often wonder why people act the way they do.  
 
    1   2                     3                        4 
very true for me          somewhat true for me    somewhat false for me         very false for me 
 
 
 
18) When good things happen to me, it affects me strongly.  
 
    1   2                     3                        4 
very true for me          somewhat true for me    somewhat false for me         very false for me 
 
 
 
19) I feel worried when I think I have done poorly at something important.  
 
    1   2                     3                        4 
very true for me          somewhat true for me    somewhat false for me         very false for me 
 
 
 
20) I crave excitement and new sensations. 
  
    1   2                     3                        4 
very true for me          somewhat true for me    somewhat false for me         very false for me 
 
 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
82 
 
21) When I go after something I use a "no holds barred" approach.  
 
    1   2                     3                        4 
very true for me          somewhat true for me    somewhat false for me         very false for me 
 
 
 
22) I have very few fears compared to my friends.  
 
    1   2                     3                        4 
very true for me          somewhat true for me    somewhat false for me         very false for me 
 
23) It would excite me to win a contest.  
 
    1   2                     3                        4 
very true for me          somewhat true for me    somewhat false for me         very false for me 
 
24) I worry about making mistakes.  
 
    1   2                     3                        4 
very true for me          somewhat true for me    somewhat false for me         very false for me 
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APPENDIX D 
Telephonic Screening Questionnaire and Brief Verbal Consent Form  
 
PARTICIPANT TELEPHONIC SCREENING QUESTIONAIRE 
 
DATE: _________________________________ 
 
A.  Personal Details: 
 
Full Name: _______________________________________ 
Date of Birth:      _______________________________________ 
Gender:  _______________________________________ 
Occupation:         _______________________________________ 
Student number: _______________________________________ 
 
 
B.  Contact Details: 
 
Address:  _______________________________________ 
   _______________________________________ 
   _______________________________________ 
 
Tel. number (h) : _______________________________________ 
                   (w):   ______________________________________ 
      (c) :   ______________________________________ 
 
Email Address: _______________________________________ 
 
 
C.  Medical Details:               Please circle  
       
1. Are you right-handed?       Yes  /  No  
 
2. Do you take any kind of medication on a regular basis?  Yes  /  No 
    If yes, please specify what kind 
____________________________________________________________________ 
 
3. Are you allergic to any medication?     Yes  /  No 
    If yes, please specify what kind 
____________________________________________________________________ 
 
4.  Have you ever had a head injury?     Yes  /  No 
     If yes, describe most severe:________________________________________ 
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    Were you knocked unconscious?     Yes  /  No 
    If yes; how long? __________________________________________________ 
 
    Any surgery/hospitalisation as a result of your head injury? Yes  /  No 
    If yes; please specify:______________________________________________ 
 
 
 
5. Do you have a metal object in your body (eg. aneurysm clip)? Yes  /  No 
    If yes, please specify:_____________________________________________ 
 
6. Do you wear a metal prosthesis (eg. artificial leg)?   Yes  /  No 
    If yes, please specify: _____________________________________________ 
 
7. Do you have a pace-maker?      Yes  /  No 
 
8.  Have you ever been diagnosed with asthma?    Yes  /  No 
 
9.  Have you ever been diagnosed with chronic bronchitis,  Yes  /  No 
     emphysema, or any other respiratory problems?                               
 
10.  Have you ever been diagnosed with a hepatic (liver)  Yes  /  No       
       problem/disorder?          
 
11.  If you are female, are you currently pregnant?   Yes  /  No 
 
 If you are female and answered no to question 10,  
      are you planning on becoming pregnant within  
      the next year?                                        Yes /  No 
  
12.  If you are female, are you currently a breastfeeding mother? Yes  /  No 
 
13. Have you ever been diagnosed with a renal problem / disorder?Yes  /  No 
 
14. Have you ever had seizures or an epileptic fit?   Yes  /  No 
 
15. Has anyone in your immediate family (siblings, parents) ever Yes  /  No 
      been diagnosed with epilepsy? 
     If yes, please specify who: ________________________________________ 
 
16. Have you ever been diagnosed with a psychiatric illness? Yes /  No 
      If yes, please specify: ___________________________________________ 
 
17. Have you ever had any neurological condition?   Yes  /  No 
     If yes, please specify: ____________________________________________ 
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18. Other notes: 
__________________________________________________________________________
__________________________________________________________________________
__________________________________________________________________________
__________________________________________________________________________
____________________________________________ 
 
 
Brief Telephonic Verbal Consent Form 
 
                                  
 
This study is entitled ‘Functional brain imaging in healthy participants with a history 
of early adversity’. It will look at the effects of the opioid, buprenorphine, on brain 
function. You will be administered a small dose of buprenorphine on 2 occasions. You 
will also perform neuropsychological tasks, undergo brain imaging, and have blood 
drawn for genetic testing.  
 
 
          Please circle  
 
1. At this stage, do you consent to participate in this study?  Yes / No 
 
2.  Do you acknowledge that all of the details (eg age & medical details) given to the 
researcher by you are correct?     Yes / No 
 
3.  Are you satisfied that any questions that you may have   Yes / No 
at this stage have been appropriately answered? 
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APPENDIX E 
F-MRI Participant Information Leaflet and Consent Form 
 
TITLE OF THE RESEARCH PROJECT: Functional brain imaging in healthy subjects 
with a history of early adversity.  
 
 
PROTOCOL NUMBER: OP-0307 
 
REFERENCE NUMBER: M07/03/010 
 
PRINCIPAL INVESTIGATOR: Professor Dan J Stein 
 
ADDRESS: MRC Anxiety & Stress Research Unit, University of Stellenbosch Department of Psychiatry/ 
University of Cape Town Department of Psychiatry 
 
CONTACT NUMBER: +27 21 938-9228  
 
Dear Volunteer 
 
You are being invited to take part in a research project.  Please take some time to read the 
information presented here, which will explain the details of this project.  Please ask the study 
staff or doctor any questions about any part of this project that you do not fully understand.  It is 
very important that you are fully satisfied that you clearly understand what this research entails 
and how you could be involved.  Also, your participation is entirely voluntary and you are free to 
decline to participate.  If you say no, this will not affect you negatively in any way whatsoever.  
You are also free to withdraw from the study at any point, even if you do agree to take part. 
 
This study has been approved by the Committee for Clinical Trials at Stellenbosch University 
and will be conducted according to the ethical guidelines and principles of the international 
Declaration of Helsinki, South African Guidelines for Good Clinical Practice and the Medical 
Research Council (MRC) Ethical Guidelines for Research. 
 
If you receive this invitation to participate, you will already have given your consent/assent to 
participate in the part of this study that is assessing the effect that Buprenorphrine has on 
individuals who have experienced a childhood traumatic event.  
 
STUDY PROCEDURES 
At each visit, besides getting the study medication from your doctor and being asked to complete 
the questionnaires and tasks, if you are agreeable you will have a type of brain scan, called an 
fMRI (functional magnetic resonance imaging) scan. As the scan is done in a relatively confined 
space, occasionally people become anxious. This does not happen often, and if you feel anxious, 
we will spend time allowing you to get used to the surroundings. During the scan, you will be 
asked to perform some simple tasks of memory and attention, which will enable the investigators 
to determine your brain function.  The scan will require you to lie on your back on a table that 
will move into the scanning machine for the hour it will take for the scan. During this time you 
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will be able to close your eyes and rest. You will also be able to talk to the study doctor/assistant 
at all times during the scan if you should experience any discomfort. The scan is a safe procedure 
if you have been screened correctly for the presence of any magnetic material on or inside you 
such as pace-makers, surgical clips and metal objects in the eyes. A formal screen for this will be 
done at the screening visit by a member of the study team. When the magnet in the machine is 
switched on, it will make some loud banging noises, but you will be clearly warned when this 
will take place. At this time you will feel nothing and the noise is not harmful to you in any way. 
To minimise the possible discomfort associated with this, we will give you some soft earplugs to 
put in .  
 
DISCOMFORT ASSOCIATED WITH THE STUDY 
There are only low or minimal risks associated with your participation in this study. If you feel 
tired at any point in any of the visits, you should please ask your study doctor/psychologist for a 
rest. If for some reason you are unable to complete a visit on a particular day we may reschedule 
to complete the assessments at another time.  
 
POTENTIAL BENEFITS 
There may be no direct benefits to you for participating in this study.  However, you will be 
making an important contribution to this research that may benefit others in the future.  We 
expect that the results of this study will help us understand the effects of apathy and depression 
on brain shape as well as memory and concentration.   
 
COMPENSATION FOR STUDY PARTICIPATION 
While you will not be paid to take part in this study, all evaluations will be provided at no cost to 
you or your medical aid.  We will however pay you for any cost incurred in attending the 
prescribed study visits.   
 
CONFIDENTIALITY 
Your participation is regarded as strictly confidential.  The results of the study will be published 
in the professional literature and made available to of the Committee for Human Research of 
Subcommittee C at the University of Stellenbosch, but your identity will not be revealed at any 
time to people outside of the study team.  
                                     
THE RIGHT TO ASK QUESTIONS/WITHDRAW FROM THE STUDY 
You have the right to ask questions at any time about any aspect of the study. If you have any 
queries, you can contact: 
Dr S Seedat: Tel (24hr contact number): 082-784-8148 
Dr P Carey: Tel (24hr contact number): 083-700-0046 
Dr D Stein: Tel (24hr contact number): 083- 263-9679 
 
Your participation in the study is entirely voluntary.  You have the right to withdraw at any time.  
If you decide to withdraw from the study, it will not jeopardize you or any future treatment you 
may require in any way. 
 
You are entitled to a signed copy of this document. 
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If you agree to take part, please complete the following section.   
 
I )………………………………………………. have been invited to take part in the above 
research project entitled Functional brain imaging in healthy subjects with a history of early 
adversity.  
The study doctor/nurse have explained the details of the study to me and I understand what they 
have said to me. 
They have also explained that this study will involve up to 5 assessments which include 
interviews, filling questionnaires, a physical examination including a blood test, and brain scan.  
I also know that I am free to withdraw from the study at any time if I am unhappy. 
By writing my name below, I voluntary agree to take part in this research project.  I confirm that 
I have not been forced in any way or by anyone to take part. 
 
Name of Participant (printed) 
 
    
Signature of Participant  Dated 
 
  
Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
 
I explained the information in this document to ………………………………….. 
I encouraged him/her to ask questions and took adequate time to answer them. 
I am satisfied that he/she adequately understand all aspects of the research, as discussed above 
I did/did not use an interpreter (if an interpreter is used, then the interpreter must sign the 
declaration below). 
 
 
Signed at (place) ......................…........…………….. on (date) …………....………... 
 
 
Signature of investigator  
 
 
 
Declaration by interpreter 
 
I (name) ……………………………………………..……… declare that: 
 
I assisted the investigator (name) ………….…………………………. to explain the information 
in this document to  ……...………………………... using the language medium of Afrikaans. 
We encouraged him/her to ask questions and took adequate time to answer them. 
I conveyed a factually correct version of what was related to me. 
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I am satisfied that the parent/legal guardian fully understands the content of this informed 
consent document and has had all his/her questions satisfactorily answered. 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2010 
 
 
Signature of interpreter  
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APPENDIX F 
Participant Information leaflet and Consent Form 
 
 
TITLE OF THE RESEARCH PROJECT: Functional brain imaging in healthy subjects with  
a history of early adversity 
 
PROTOCOL NUMBER: OP-0307 
 
REFERENCE NUMBER: M07/03/010 
 
PRINCIPAL INVESTIGATOR: Professor Dan J Stein 
 
ADDRESS: MRC Anxiety & Stress Research Unit, University of Stellenbosch Department of 
Psychiatry/ University of Cape Town Department of Psychiatry 
 
CONTACT NUMBER: +27 21 938-9228  
 
 
You are being invited to take part in a research project.  Please take some time to read the 
information presented here, which will explain the details of this project.  Please ask the study 
staff or doctor any questions about any part of this project that you do not fully understand.  It is 
very important that you are fully satisfied that you clearly understand what this research entails 
and how you could be involved.  Also, your participation is entirely voluntary and you are free 
to decline to participate.  If you say no, this will not affect you negatively in any way 
whatsoever.  You are also free to withdraw from the study at any point, even if you do agree to 
take part. 
 
This study has been approved by the Committee for Clinical Trials at Stellenbosch University and will be conducted according to the ethical 
guidelines and principles of the international Declaration of Helsinki, South African Guidelines for Good Clinical Practice and the 
Medical Research Council (MRC) Ethical Guidelines for Research. 
 
This trial is being run at the Department of Psychiatry, University of Stellenbosch. We aim to 
recruit a total of 40 participants over a period of 2 years 
 
What is this research study all about?  
The purpose of this study is to find out what effects Buprenorphrine has on individuals who have 
experienced a childhood traumatic event. This study will make comparisons between treatments.  
Randomisation means that the participants are put into treatment groups by chance.  The groups 
are selected by a computer that has no information about the individual participants.  Participants 
in each group (Buprenorphrine or placebo) then have a different treatment and their responses 
are then compared.  
In a blinded study the treatment provided will be hidden or concealed so you will not know 
which treatment you will receive. This research study is called "double blind". In a double blind 
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research study neither you nor your study doctor will know in which treatment group you are 
(although if your doctor needs to find out he/she can do so). 
 
A placebo is a dummy treatment such as a pill or a capsule, which looks like the real thing but is 
not. Placebo medications do not contain active ingredients. 
 
In a crossover study you will first receive one treatment and then the other. If you agree to take 
part in this study you will be given either Buprenorphrine or placebo on one visit and the other 
(either Buprenorphrine or placebo) on the following visit.  
 
Procedures 
If you agree to take part in the study and if you meet all of the conditions required to enter the 
study, you will have the following tests and procedures: 
At the first clinic visit the study investigator will ask you some questions to determine whether 
you suffer from any psychiatric disorders. If you are eligible and agree to participate in the study 
you will be asked to attend the clinic on up to 4 more occasions. You will receive study 
medication or placebo from the study nurse on the day of your visit. You will then be asked to 
complete questionnaires. You will also be asked to complete some computerised tasks, and will 
have a brain image scan done0839638265 during some of the sessions (if you agree to do so). 
 
At each visit a record will be kept of  any medications that you are taking currently or have taken 
recently. A record will also be taken of any side effects that you may be experiencing. 
 
 
Blood samples (about 30 ml [6 tablespoons]) will be collected for routine laboratory testing, for a 
pregnancy test (if you are female) and for possible future genetic studies. 
You will be asked to have your blood drawn on the first day of attendance.  Approximately 12ml 
of blood will be drawn from your arm.  We may need to contact you again to get another blood 
sample should we fail to get a DNA sample from your blood.  The blood sample you give may 
be used to create a cell line.  This is done by changing some of your blood cells so that they can 
grow forever.  The cell line is living tissue and it can be used to make more of your DNA at any 
time in the future.  Candidate polymorphisms identified to be associated with anxiety or 
depression and possibly playing a role in explaining variance in the fMRI results will be 
investigated later on.  This process will take place at the MRC Centre for Molecular and Cellular 
Biology and the Division of Medical Biochemistry, Faculty of Health Sciences, at the University 
of Stellenbosch, as well as at the Centre for Proteomics and Genomics Research (CPGR) at the 
University of Cape Town.  The DNA will then be taken from the cell line and saved for scientific 
analyses which will be performed now, and possibly in the future.   
 
We may contact you later for further information, or request you to complete another interview 
at a later date, in order to obtain follow-up information that may be of use in our genetic 
analyses.  This may involve an assessment similar to the current assessment, including a series of 
interviews and/or another blood sample.  Your current participation is in no way binding to your 
future participation. 
 
Un
ive
rsi
ty 
of 
Ca
pe
 To
wn
92 
 
Your cell line and DNA will be maintained permanently, unless you request to have it removed.  
If at any time in the future you wish to have your DNA, cell lines or clinical data removed from 
the storage site, you may do so by contacting the researchers conducting this study. 
 
 
 
Why have you been invited to participate? 
You have been invited to participate in this study because you may have been exposed to a 
traumatic event in your childhood. We would like to see if this medication will impact 
differences in people’s performance on certain tasks which may be associated with having 
experienced early adversity.  
 
What will your responsibilities be? 
The study investigator will be required to ask you about medications that you may be taking 
currently or that you may have taken recently. Your study investigator  will explain to you which 
medications need to be stopped during the entire length of the study and how soon before you 
take part in the study these medications must be stopped. 
 
Your doctor will also advise you on which prescription or over-the-counter medications or any 
other remedies or foods that you will be required to either stop or restrict your consumption of 
during the entire length of the study. This will include a restriction on the amount of alcohol that 
can be consumed. 
 
At each visit you may be asked to complete questionnaires or tasks to check the status of your 
symptoms. These will measure your mood, emotional responses, trust, sociability and emotional 
resilience. 
 
Will you benefit from taking part in this research? 
Your participation in this study will add to the medical knowledge about the use of this 
medicine. 
 
The information learned from this study may help to establish a new medication for the treatment 
of people who have been exposed to trauma in their childhoods. 
 
Are there in risks involved in your taking part in this research? 
All drugs and even placebos may cause side effects in some people. There may be risks, 
inconveniences or side effects that are not known at this time. 
 
The most commonly reported adverse reactions of  Buprenorphrine administration are 
constipation, headaches, insomnia, asthenia, drowsiness, nausea and vomiting, fainting and 
dizziness, orthostatic hypotension, sweating. 
 
Special caution should be exercised when driving or using machinery since the study medication 
may cause drowsiness. 
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You will receive both Buprenorphrine and placebo, each at a separate visit. As mentioned earlier 
this research study is called "double blind". In a double blind research study neither you nor the 
study investigator will know in which treatment group you are. It is possible that you may not 
experience any side effects when receiving treatment. This does not mean that you have received 
placebo. Similarly, even if you do receive placebo you may experience some side effects which 
you and your doctor feel could be associated with the study drug. 
 
Because the effects of Buprenorphrine on the unborn foetus (child/baby) or nursing baby/infant 
are uncertain, you will not be allowed to enter this study if you are pregnant or breastfeeding or 
planning to become pregnant within 6 weeks of your screening visit. 
 
If you choose to participate in this study, you must use one of the allowed contraceptive methods 
(a way to prevent you from becoming pregnant) for the specified period of time before and after 
you enter the study. Ask your doctor if you have any questions about these choices and which 
might be best for you. 
 
Acceptable contraceptive methods, when used consistently and in accordance with both the 
product label and the instructions of your doctor, are as follows: 
 
a Non-childbearing potential (i.e., physiologically incapable of becoming pregnant, including 
being post-menopausal. For purposes of this study, postmenopausal is defined as one year 
without menses); or 
b Child-bearing potential, you must agree to one of the following: 
• Male partner who is sterile prior to your entry into the study and is your sole sexual 
partner; 
• Oral contraceptives (either combined or progestogen only); 
• Double-barrier method of contraception consisting of spermicide with either condom or 
diaphragm;  
• IUD with a documented failure rate of less than 1% per year; or 
 
 
Even when you use one of the allowed contraceptive methods, there may be a small risk that you 
could become pregnant. Because of this, you will be tested during the study to see if you are 
pregnant. If one of these tests shows that you have become pregnant, your unborn baby may have 
been exposed to Buprenorphrine even if you stop taking the drug right away. So, if you think you 
are pregnant or may become pregnant, you must tell Dr_________________________ at the 
earliest opportunity. If you should become pregnant during the study you will be asked, required 
or requested to, stop taking the study drug immediately. You will also be followed to determine 
the outcome of the pregnancy. Generally, follow-up will be no longer than 6 to 8 weeks 
following the estimated delivery date. Any premature termination of the pregnancy must be 
reported to your study doctor. 
 
There may be other risks, inconveniences and side effects to the embryo, foetus (unborn child), 
or nursing infant that are unknown at this time. 
 
If you do not agree to take part, what alternatives do you have? 
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Before you decide whether or not to take part in this study, you may wish to consider other 
treatment options.  Your study doctor will describe these to you based on your medical history 
and the treatment you have received to date.  
 
Who will have access to your medical records? 
Maintaining your confidentiality is important. Your personal information (for example your 
gender, age, the details of your medical conditions) and other information (the data collected by 
the investigators as part of the study) will be identified by a number (i.e., coded). Your name will 
not appear in any publications or reports produced from this study. The investigators will keep 
the information and the results collected about you in this study. This information about you will 
be kept in a secure place. By agreeing to take part in this study, you will be allowing certain 
persons to see the information about you (both personal, including your name, and other 
information) held by the study doctor. You have the right to withdraw your consent to participate 
in this study at any time. If you withdraw your consent to participate in this study no new 
information will be collected from you and added to existing data or to a database. Your 
information will be processed electronically (i.e., by a computer) or manually and analysed to 
determine the outcome of this study. Your information may/could be sent to regulatory 
authorities and to the Ethics Committees. You have the right to ask the study doctor about the 
data being collected on you for the study and about the purpose of this data. You have the right 
to ask the study doctor to allow you to see your personal information and to have any necessary 
corrections made to it. 
 
What will happen in the unlikely event of some form of injury occurring as a direct result 
of your taking part in this research study? 
If you become ill or injured as a result of participation in this clinical study, you will be referred 
for appropriate medical treatment. The University of Stellenbosch’s insurance policy will cover 
the costs of such treatment. If you have any questions concerning the availability of 
compensation/medical care or if you think you have experienced a research-related illness or 
injury, contact details are below. 
 
Your right at law to claim compensation for injury where you can prove negligence is not 
affected.  For medicines that have already been approved by the Medical Authorities to treat this 
condition, normal legal rules on compensation will apply. 
If you have any questions about your rights as a research subject, you should contact the 
Committee for Pharmaceutical Trials of the University of Stellenbosch, Tel: (021) 938 9075, 
Fax:  (021) 933-6330. 
 
If you have questions about this trial you should first discuss them with your study doctor or the 
Committee for Pharmaceutical Trials of the University of Stellenbosch.  
Dr S Seedat: Tel (24hr contact number): 082-784-8148 
Dr P Carey: Tel (24hr contact number): 083-700-0046 
Dr D Stein: Tel (24hr contact number): 083- 263-9679 
 
After you have consulted your doctor or the ethics committee and if they have not provided you 
with answers to your satisfaction, you should write to the South African Medicines Control 
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Council (MCC) at: The Registrar, SA Medicines Control Council, Department of Health, Private 
Bag x 828, Pretoria, 0001, Fax: (012) 323 4474 
 
Will you be paid to take part in this study and are there any costs involved? 
 
No you will not be paid to take part in the study but your transport and meal costs (R150) will be covered for each study visit.  There will 
be no costs involved for you, if you do take part. 
 
Is there any thing else that you should know or do? 
¾ You can contact Dr ……………….………..….. at tel ……………………… if you have any further queries or encounter any 
problems. 
¾ You can contact the Committee for Human Research at 021-938 9207 if you have any concerns or complaints that have not 
been adequately addressed by your study doctor. 
¾ You will receive a copy of this information and consent form for your own records. 
 
 
Declaration by participant 
 
By signing below, I …………………………………..…………. agree to take part in a research 
study entitled (insert title of study). 
 
I declare that: 
 
• I have read or had read to me this information and consent form and it is written in a 
language with which I am fluent and c mfortable. 
• I have had a chance to ask questions and all my questions have been adequately 
answered. 
• I understand that taking part in this study is voluntary and I have not been 
pressurised to take part. 
• I may choose to leave the study at any time and will not be penalised or prejudiced in 
any way. 
• I may be asked to leave the study before it has finished, if the study doctor or 
researcher feels it is in my best interests, or if I do not follow the study plan, as 
agreed to. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2010. 
 
 
 
 ..........................................................................................................   .......................................................................................................  
Signature of participant Signature of witness 
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Declaration by investigator 
 
I (name) ……………………………………………..……… declare that: 
 
• I explained the information in this document to ………………………………….. 
• I encouraged him/her to ask questions and took adequate time to answer them. 
• I am satisfied that he/she adequately understands all aspects of the research, as 
discussed above 
• I did/did not use an interpreter.  (If an interpreter is used then the interpreter must 
sign the declaration below. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2010. 
 
 
 
 ..........................................................................................................   .......................................................................................................  
Signature of investigator Signature of witness 
 
 
Declaration by interpreter 
 
I (name) ……………………………………………..……… declare that: 
 
• I assisted the investigator (name) ………………………………………. to explain 
the information in this document to (name of participant) 
……………..…………………………….. using the language medium of Afrikaans. 
• We encouraged him/her to ask questions and took adequate time to answer them. 
• I conveyed a factually correct version of what was related to me. 
• I am satisfied that the participant fully understands the content of this informed 
consent document and has had all his/her question satisfactorily answered. 
 
 
Signed at (place) ......................…........…………….. on (date) …………....……….. 2010. 
 
 
 
 ..........................................................................................................   .......................................................................................................  
Signature of interpreter Signature of witness 
